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ABSTRACT 
 
Genetic alterations in epilepsy: the cases of Unverrich-Lundborg disease, 
Fragile-X and B1 null mutation 
 
 
Genetic mechanisms are estimated to underlie about 40% of epilepsies and may present with 
different manifestations and syndromes. In this thesis, three different cases of genetic implications 
in epilepsy have been studied: Unverricht-Lundborg disease (ULD), a monogenic Progressive 
Myoclonic Epilepsy in which disruption of the cystatin B gene results in the manifestation of the 
pathology; Fragile X, the most frequent genetic mental retardation disease which associates to 
epileptic seizures in about 25% of the cases; and involvement of the bradykinin system in epilepsy, 
a possible cause of latent hyper-excitability.  
The study on ULD revealed increased brain excitability in mice deficient for cystatin B, the genetic 
defect associated with the pathology. This hyperexcitability seems to be related to a decreased 
inhibitory cell number and/or to the activation of microglia. Our findings on Fragile-X reveal that, 
after a chemically induced epileptic event (pilocarpine status epilepticus), active synapses 
accumulate Fmr1 mRNA and its protein, FMRP. This phenomenon may account for an involvement 
in activity-dependent synaptic plasticity and epileptogenesis. Finally, we studied bradykinin 
involvement in brain excitability, and found that electrical (kindling) and chemical (kainate) 
epileptic insults exacerbate a latent tissue hyper-excitability in B1 null mice. 
These findings are examples of how genetic alterations may alter brain function, directly or 
indirectly leading to epilepsy manifestations. In depth, investigation of the different aspects of the 
genetic mechanisms of epilepsy is very important to identify key factors that, in the end, may allow 
discovering new therapeutic targets and new treatments. Moreover, study of the basic mechanisms 
underpinning pathological events may also shed light on the normal brain function.  
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RIASSUNTO 
 
Genetic alterations in epilepsy: the cases of Unverrich-Lundborg disease, 
Fragile-X and B1 null mutation 
 
 
Si stima che intorno al 40% dei casi di epilessia abbiano un’eziologia genetica. Le epilessie 
genetiche possono manifestarsi con una elevata varietà di sintomi e differenti forme di crisi. In 
questa tesi abbiamo studiato tre aspetti di questo fenomeno: la patologia di Unverricht-Lundborg 
(ULD), un esempio di epilessia monogenetica dovuta a mutazioni del gene per la cistatina B; la 
sindrome dell’X Fragile (FX), la più diffusa forma di ritardo mentale dovuta a cause genetiche (la 
mutazione del gene Fmr1), che si associa a fenomeni epilettici nel 25% dei casi; ed infine il 
coinvolgimento delle bradichinine nell’epilessia, una possibile causa di iper-eccitabilità latente e 
quindi una possibile classe di geni predisponesti alla malattia. 
Gli studi sull’ULD hanno dimostrato una maggiore eccitabilità tissutale dei topi KO per la cistatina 
B, probabilmente riconducibile ad una perdita di neuroni inibitori e/o all’attivazione della microglia. 
Nello studio sull’FX, l’analisi molecolare dell’insulto epilettico da pilocarpina ha dimostrato che le 
sinapsi attive accumulano l’mRNA di fmr1 e il suo prodotto proteico, FMRP, implicando un loro 
ruolo nella plasticità sinaptica attività-dipendente e nell’epilettogenesi. Infine, abbiamo studiato il 
coinvolgimento della bradichinina nell’eccitabilità cerebrale, e abbiamo scoperto che la delezione 
del gene codificante il recettore B1 per le bradichinine comporta una ridotta resistenza alle crisi 
indotte da kindling e da kainato, espressione di una latente iper-eccitabilità. 
I dati raccolti in questa tesi rappresentano esempi di come le alterazioni genetiche possano, 
direttamente o indirettamente, alterare la funzione del cervello e causare manifestazioni di tipo 
epilettico. Lo studio approfondito delle alterazioni genetiche in epilessia è importante ai fini di 
identificare bersagli molecolari idonei per lo sviluppo di nuovi farmaci o terapie adeguate. Non solo: 
lo studio dei meccanismi che sottendono eventi patologici può anche aiutarci a spiegare il normale 
funzionamento del cervello.   
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Chapter I 
 
Epilepsy 
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GENERALITIES 
 
 
Epilepsy and its definition 
 
Through centuries, epilepsy has been described and defined in different ways based on knowledge 
and superstition of the different ages. Several times epilepsy was associated to divinity, in a good or 
bad fashion, charging this disease of a magical aura that sometimes survive even to date. 
Hippocrates, around the 4th century B.C., was among the first describing epilepsy as an ordinary, 
and not having magical properties, pathology, which origins from the brain. Since then, several 
other definitions and approaches alternated in time to describe and treat this pathology, resulting in 
the most peculiar and sometimes ridiculous ways to face the problem.  
First clinically defined by John Hughlings Jackson as “an occasional sudden, excessive, rapid and 
local discharge of grey matter”, epilepsy, mainly due to its semiology, is still difficult to properly 
define.  
The International League Against Epilepsy and the International Bureau for Epilepsy define 
epilepsy as “a disorder of the brain characterized by an enduring predisposition to generate 
epileptic seizures and by the neurobiologic, cognitive, psychological, and social consequences of 
this condition. The definition of epilepsy requires the occurrence of at least one epileptic seizure” 
(Fisher et al, 2005).  
Therefore, the term “epilepsy” indicates a brain disorder characterized predominantly by recurrent 
and unpredictable interruptions of normal brain function, called seizures. Epilepsy is not a singular 
disease entity but a variety of disorders reflecting underlying brain dysfunction that may result from 
many different causes. This pathology is not one condition but is a diverse family of disorders, 
having in common an abnormally increased predisposition to seizures, that are defined as “transient 
occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal 
activity in the brain.” (Fisher et al, 2005). Discussion about a few points of this new definition of 
epilepsy is raging, mainly related to: 1) abolishment of the concept of “unprovoked seizure”; 2) 
absence of the “two seizures” criteria; 3) lack of clear clinical definition of the “enduring alteration 
in the brain that increases the likelihood of future seizures” (Ahmed et al, 2005; Beghi et al, 2005; 
Gomez-Alonso et al, 2005).  
Therefore, debate on a proper statement which will exhaustively define epilepsy is still a central 
point in the scientific community, because of its importance in terms of medical, legislative and 
education communication (Fisher et al, 2005). 
 
 8
Epidemiology  
 
About 1% of world population is estimated to be affected by epilepsy (prevalence), which makes 
this disease one of the most common neurological disorders. Age specific incidence of epilepsy is 
higher in children (0-14 years) and in elderly (>60 years) than in adult individuals (15-59 years) 
(respectively mean incidence rates of epilepsy are: 82,2/100000 per year – 39,7/100000 per year – 
34,7/100000 per year; total incidence rate is 47,4/100000 per year). Incidence rate for age-specific 
epilepsy distribution is significantly different. A non significant trend to higher incidence of 
epilepsy in males compared to females has been reported showing respectively mean incidence 
rates of 50,7/100000 per year and 46,2/100000 per year (Kotsopoulos et al, 2002; McHugh and 
Delanty, 2008). Incidence seems to be higher in males due to the greater exposure to risk factors 
that cause symptomatic epilepsies. Generally, the median seizure-specific incidence rates are higher 
for partial (34,4/100000 per year) than for generalized seizures (19,6/100000 per year), but this 
difference is not significant. The incidence of epilepsy appears to differ from country to country and 
to change over time. Indeed the incidence rate results to be different in industrialized countries (40-
70/100000) compared to the resource-poor countries (100-190/100000) where incidence tends to 
double. Moreover, in this case, higher rates are found in children and adults than in the elderly. 
Incidence can change also over time as demonstrated by two studies by Hauser and Kurland, 1975 
and Houser et al, 1993 and by Forsgren, 1990 and Forsgren et al, 1996. In these reports, incidence 
for epilepsy changes with age, doubling for elderly individuals over the young in Hauser studies, 
and showing a higher incidence for unprovoked seizures in adults in Forsgren studies. Several 
factors may be involved in this pattern, such as improved antenatal and prenatal care for children, 
and an increase in life expectancy in the elderly, associated with an increased risk for causes of 
epilepsy common in old age (for a review see Kotsopoulos et al, 2002; McHugh and Delanty, 2008; 
Sander, 2003) 
 
Epidemiology terms: 
Prevalence: In epidemiology, the prevalence of a disease in a statistical population is defined as the total number of cases of the disease in the 
population at a given time, or the total number of cases in the population, divided by the number of individuals in the population. It is used as an 
estimate of how common a condition is within a population over a certain period of time. It helps physicians or other health professionals understand 
the probability of certain diagnoses and is routinely used by epidemiologists, health care providers, government agencies, and insurance companies. 
Mathematically prevalence can be defined as follows: the ratio between the number of individuals in the population with the disease at a given time  
(a) divided by the sum of individuals in the population with the disease at a given time (a) and  individuals in the population without the disease at a 
given (b).  
Prevalence= a/(a+b) 
Incidence: Incidence is a measure of the risk of developing some new condition within a specified period of time. Although sometimes loosely 
expressed simply as the number of new cases during some time period, it is better expressed as a proportion or a rate with a denominator. 
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Incidence proportion (also known as cumulative incidence) is the number of new cases within a specified time period divided by the size of the 
population initially at risk. For example, if a population initially contains 1,000 non-diseased persons and 28 develop a condition over two years of 
observation, the incidence proportion is 28 cases per 1,000 persons, i.e. 2.8%. 
The incidence rate is the number of new cases per unit of person-time at risk. In the same example as above, the incidence rate is 14 cases per 1000 
person-years, because the incidence proportion (28 per 1,000) is divided by the number of years (two). Using person-time rather than just time 
handles situations where the amount of observation time differs between people, or when the population at risk varies with time. Use of this measure 
implicitly implies the assumption that the incidence rate is constant over different periods of time, such that for an incidence rate of 14 per 1000 
persons-years, 14 cases would be expected for 1000 persons observed for 1 year or 50 persons observed for 20 years. 
Incidence should not be confused with prevalence, which is a measure of the total number of cases of disease in a population, rather than the rate of 
occurrence of new cases. Thus, incidence conveys information about the risk of contracting the disease, whereas prevalence indicates how widespread 
the disease is. 
 
 
Treatment 
 
Epilepsy treatment is symptomatic, mainly aiming to control seizure recurrence, and only surgery 
can be sometimes curative. No currently available drug is capable of preventing epileptogenesis. 
Anti-epileptic drugs (AEDs), better if called anticonvulsants, target different biological substrates 
such as voltage-gated Na-channel (e.g. Phenytoin and its derivatives), GABA system (e.g 
Barbiturate or Benzodiazepine) and voltage-gated Ca-channels (ethosuximide) (Tab 1). 
 
Table 1: Anti-Epileptic Drugs  
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N
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MECHANISM 
OF ACTION TREATMENT ADMINISTRATION SIDE EFFECTS 
      
18
57
 
Br
om
id
e 
(P
ot
as
siu
m
 
br
om
id
e)
 
 Frequently used 
as sedatives in 
the 19th and early 
20th century , 
bromide ion is 
antiepileptic, and 
bromide salts are 
still used as such, 
particularly in 
veterinary 
medicine 
 Loss of appetite, nausea/emesis, lethargy, propensity to 
sleep during the daytime, depression, loss of 
concentration and memory, confusion, headache, and  
Bromism Acne-form dermatitis and other forms of skin 
disease may also be seen, as well as mucous hyper 
secretion in the lungs. Asthma and rhinitis may worsen. 
Rarely, tongue disorder, aphten, bad breath, and 
constipation occur. 
19
12
 
Ph
en
ob
ar
bi
ta
l 
Regulate 
Chloride 
permeability 
reducing 
excitatory effects 
of 
neurotransmitters 
Still used as 
AED. It is used to 
treat generalized 
convulsive  
seizures, 
myoclonus and 
partial seizures. It 
is also used in 
childhood febrile 
seizures  
50-300mg  once a day Sedation and hypnosis are the principal side effects of 
phenobarbital. Central nervous system effects like 
dizziness, nystagmus and ataxia are also common. In 
elderly patients, it may cause excitement and confusion 
while in children, it may result in paradoxical 
hyperactivity. 
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19
38
 
Ph
en
yt
oi
n 
Regulate sodium 
channel 
permeability 
Effective in 
treating partial 
and generalized 
convulsive 
seizures, 
particularly 
partial convulsive 
seizures.  
100-600mg per day, 
per os. Intravenous 
administration is used 
when patient is on 
status epilepticus. 
At therapeutic doses, phenytoin produces nystagmus, At 
toxic doses, patients experience sedation, cerebellar 
ataxia, and ophthalmoparesis, as well as paradoxical 
seizures. Idiosyncratic side effects are rash and severe 
allergic reactions. Phenytoin may cause atrophy of the 
cerebellum when administered at chronically high levels. 
Phenytoin predispose patients to megaloblastic anemia 
and gingival hyperplasia. Phenytoin is a known teratogen 
and suggested to be carcinogenic. Phenytoin has been 
known to cause Drug-induced Lupus and other dangerous 
or even fatal skin reactions. (such as Stevens-Johnson 
syndrome and toxic epidermal necrolysis) 
19
52
 
Pr
im
id
on
e 
Methabolized by 
the liver in 
Phenobarbital has 
its same 
mechanism of 
action  
See 
Phenobarbital 
250-1000mg, two or 
three times per day. 
See  Phenobarbital 
19
55
 
Et
ho
su
xi
m
id
e 
Primary thalamic 
regulation of 
Calcium channel 
permeability 
Used for absence 
seizures. 
500-2000mg  CNS common side effects are drowsiness, mental 
confusion, insomnia, nervousness, headache, euphoria, 
ataxia, hiccups, impaired, concentration, irritability, 
hyperactivity, loss of taste, night terrors. Gastrointestinal 
side effects are dyspepsia, vomiting, nausea, cramps, 
constipation, diarrhea, stomach pain, loss of appetite, 
weight loss, gingival hyperplasia, swelling of tongue. 
Other side effects involves Genitourinary Hematopoietic 
Integumentary Ocular apparatus. 
19
63
 
Ba
rb
ex
ac
lo
ne
 
Regulate 
excitability by 
modulation of 
chloride 
channels. When 
associated to 
phenobarbital has 
awakening 
properties  
exerted by the 
propylexidine 
component. 
Treatment of 
generalized 
convulsive 
seizures and 
partial seizures. 
25-200mg  See Phenobarbital. Better tolerated than Phenobarbital. 
19
66
 
Ca
rb
am
az
ep
in
e 
Regulate sodium 
channel 
permeability  
Drug of choice 
for partial 
seizures. Used 
also in partial and 
generalized 
convulsive 
seizures.  
400-2400mg  Its common side effects include drowsiness, headaches 
and migraines, motor coordination impairment and/or 
upset stomach. Carbamazepine decrease tolerance to 
alcohol. 
Less common side effects include cardiac arrhythmias, 
blurry or double vision and/or the temporary loss of 
blood cells or platelets and in rare cases can cause 
aplastic anemia. Additionally, carbamazepine may 
exacerbate pre-existing cases of hypothyroidism, there 
are also reports of auditory side effects. 
19
72
 
Va
lp
ro
at
e 
Potenziate 
GABA inhibitory 
activity and 
modulate sodium 
channel 
permeability.  
Effective for all 
kind of seizures, 
it represent the 
drug of choice for 
primary 
generalized 
seizures and for 
benign epilepsy 
with partial 
seizures  
600-3000mg  Common side effects are dyspepsia and/or weight gain. 
Less common are fatigue, peripheral edema, dizziness, 
drowsiness, hair loss, headaches, nausea, sedation and 
tremors. Valproic acid also causes hyperammonemia, 
which can lead to brain damage. Rarely, valproic acid can 
cause blood dyscrasia, impaired liver function, jaundice, 
thrombocytopenia, and prolonged coagulation times. 
Valproic acid may also cause acute haematological 
toxicities cognitive dysfunction and reversible pseudo-
atrophic brain changes. It is known as a teratogenic agent.
19
74
 
Cl
on
az
ep
am
 
Increases GABA 
action 
Treatment for 
partial seizures. 
0.5-8mg used 
intravenously in status 
epilepticus with 
dosage evaluated 
patient by patient. 
Common side effects are drowsiness, impairment of 
cognition and judgment, irritability and aggression, 
psychomotor agitation, lack of motivation, impaired 
motor function, cognitive impairments. Occasional and 
rare side effects are serious dysphoria, 
Thrombocytopenia, serious psychological and psychiatric 
side effects, induction of seizures or increased frequency 
of seizures, personality changes, psychosis, incontinence, 
paradoxical behavioural disinhibition 
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88
 
Ac
et
az
ol
am
id
e 
Inhibits CO2 
catabolism 
increasing its 
concentration in 
the CNS. This  
modify the 
membrane 
excitability and 
the modulation of 
buffer function of 
glial cells.  
Useful for all 
kind of seizures, 
but more often 
used for  absence 
seizures.  
250-750mg in 
association with other 
AEDs.   
Common side effects include numbness and tingling in 
the fingers and toes, taste alterations (parageusia), 
frequent urination, and blurred vision, but this usually 
disappears shortly after stopping the medication. 
Acetazolamide also increases the risk of developing 
calcium oxalate and calcium phosphate kidney stones.  
 
19
89
 
Fe
lb
am
at
e Reduces Glycine action 
Used for the 
treatment of 
partial seizures 
and secondarily 
generalized  
1200-3600mg in 
association with other 
AEDs.   
Side effects include decreased appetite, vomiting, 
insomnia, nausea, dizziness, somnolence, and headache. 
Many patients report increased alertness with the drug. 
Two rare but very serious effects include aplastic anemia 
and hepatic (liver) failure.  
19
89
 
Vi
ga
ba
tri
n 
Potenziate 
GABA action 
blocking its 
catabolic enzyme.  
Used for the 
treatment of 
partial seizures 
and secondarily 
generalized 
1000-3000mg, in 
association with other 
AEDs.   
CNS side effects are somnolence, headache, dizziness, 
nervousness, depression, memory disturbances, diplopia, 
aggression, ataxia, vertigo, hyperactivity, vision 
abnormalities, confusion, insomnia, impaired 
concentration, personality disorder. 11% of children 
become hyperactive. Some patients develop psychosis 
during the course of vigabatrin therapy. Other rare CNS 
side effects include anxiety, emotional lability, 
irritability, tremor, abnormal gait, and speech disorder. 
Gastrointestinal side effects are abdominal pain, 
constipation, vomiting, and nausea.  
19
91
 
La
m
ot
rig
in
e 
Regulate sodium 
channels 
reducing the 
effects of 
excitatory 
neurotransmitters 
Used for the 
treatment of 
partial seizures 
and secondarily 
generalized it is 
also effective for 
treatment of 
many kinds of 
primary or 
idiopathic 
generalized 
seizures  
50-600mg, in 
association with other 
AEDs.   
Common side effects include headaches, dizziness and 
insomnia. Other side effects may include acne and skin 
irritation, vivid dreams or nightmares, night sweats, body 
aches and cramps, muscle aches, dry mouth, fatigue, 
memory and cognitive problems, irritability, weight 
changes, hair loss, changes in libido, frequent urination, 
nausea, and other side effects. In very rare cases, 
Lamotrigine has been known to cause the development of 
a dangerous rash called Stevens-Johnson syndrome (or 
SJS). 
19
93
 
G
ab
ap
en
tin
 
Increases 
inhibitory activity 
of GABA 
Used for the 
treatment of 
partial seizures 
and secondarily 
generalized 
900-2400mg, in 
association with other 
AEDs.   
Most common side effects include dizziness, drowsiness, 
and peripheral edema (swelling of extremities). Children 
3–12 years of age were observed to be susceptible to 
mild-to-moderate mood swings, hostility, concentration 
problems, and hyperactivity. Rare side effects are 
represented by cases of hepatotoxicity. Gabapentin 
should be used carefully in patients with renal 
impairment due to possible accumulation and toxicity. It 
has a carcinogenic potential.  
19
95
 
To
pi
ra
m
at
e 
Modulate voltage 
dependent 
sodium channels. 
Potentiate 
inhibitory activity 
of GABA and 
reduces 
excitatory 
activity of 
AMPA-Kainate 
neurotransmitters 
Used for the 
treatment of 
partial seizures 
and secondarily 
generalized it is 
also effective for 
treatment of 
many kinds of 
primary or 
idiopathic 
generalized 
seizures 
200-600mg, in 
association with other 
AEDs.   
The most often reported side effects are tiredness, pins 
and needles in the fingers and toes, dizziness, lowered 
sense of feeling in the skin, difficulty with language, 
nausea, diarrhoea, indigestion, dry mouth, weight loss, 
decrease in appetite, drowsiness, forgetfulness, difficulty 
with concentration or attention, difficulty in sleeping 
(insomnia), anxiety, mood swings, depression, changes in 
taste and vision disorders. Rare side effects are blood 
clots, blurring of vision and eye pain, reduced sweating  
and metabolic acidosis 
 
 
19
98
 
Ti
ag
ab
in
e 
Increases GABA 
action 
maintaining 
GABA at 
synaptic level for 
longer time. 
Used for the 
treatment of 
partial seizures 
and secondarily 
generalized 
30-50mg, in 
association with other 
AEDs.   
Its side effects include confusion, difficulty speaking 
clearly/stuttering, mild sedation, and, in doses over 8 mg, 
paresthesia in the body's extremities, particularly the 
hands and fingers. 
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20
00
 
O
xc
ar
ba
ze
pi
ne
 
See 
Carbamazepine 
See 
Carbamazepine 
600-3000mg  Oxcarbazepine causes dizziness, drowsiness, blurred or 
double vision, fatigue and may cause headaches, nausea, 
vomiting and stomach pain, diarrhoea, constipation and 
dry mouth. It can also cause hyponatremia. Concentration 
loss is also reported to be a frequent side effect. Skin 
sensitivity to sunlight also may increase. 
20
01
 
Le
ve
tir
ac
et
am
 
Binds synaptic 
sites of CNS and 
modulates 
neuronal burst 
inhibiting 
epileptic 
discharges.  
Used for the 
treatment of 
partial seizures 
and secondarily 
or idiopathic 
generalized 
epilepsies  
500-1000mg, two or 
three times per day 
Side effects include: hair loss; pins and needles sensation 
in the extremities; anxiety and psychiatric symptoms 
ranging from irritability to depression; and other common 
side effects like headache and nausea. It is generally well 
tolerated[6] but may cause sleepiness, weakness, 
dizziness, and infection. In children, the most common 
side effects are sleepiness, accidental injury, hostility, 
irritability, and weakness. 
20
01
 
Cl
ob
az
am
 Increases GABA 
action 
Effective on 
partial seizures  
10-40mg, in 
association with other 
AEDs.   
Common side effects are ataxia, somnolence, diplopia, 
dysarthria and rarely gelastic seizures and urticaria rashes
 
The choice among the different AEDs depends on the semiology of the disease and the management 
of the treatment is correlated to the containment of seizures: some patients reach the goal by a 
monotherapy, some others, unfortunately, require polytherapy with the use of two or more AEDs. 
Balance between control of seizures and side effects of AEDs is another important point that 
physicians must take into consideration when starting a treatment for epilepsy. Medication 
administration is sometimes life-long lasting, some other times it could be slowly withdrawn, 
depending on recurrence of seizures when drugs are stopped. In spite of the numerous AEDs 
available, several patients are refractory to pharmacological treatments and continue to experience 
seizures. Indeed, of those who develop epileptic seizures 47% will be controlled with the first AED 
prescribed, 32% with the second AED, and 9% with the third. Fourth and subsequent AEDs have at 
most a 5% chance of bringing remission (Duncan, 2007). This leaves around 7% of individuals that 
have no chances to control their seizures by pharmacological approaches. Therefore it is of central 
importance to develop new drugs able to contain seizures or even to prevent epileptogenesis. This 
latter goal could be reached, not only by empirical experimentation of new chemical compounds, 
but also by increasing our knowledge of the complex basis of the pathology. When drug treatments 
result ineffective and patients experience refractory seizures, other medical approaches may be 
applied. These alternative treatments include surgery, vagus nerve stimulation, ketogenic diet, 
avoidance therapy. 
Epileptic surgery is a delicate tool that does not apply to any kind of epileptic patient. Best 
candidate for surgery are those individuals that continue to experience seizures despite the fact they 
are under pharmacological treatment. Focal and very localized epileptic lesions are the target for 
surgery and only epilepsy with these anatomical characteristics must be taken into consideration 
when surgery is to apply. Surgery follows after a full assessment of the epileptic conditions. Video-
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electroencephalogram monitoring, neuropsychological examination, structural magnetic resonance 
imaging, functional imaging tests and intracranial electrode recordings are tools used to identify the 
type of epilepsy, determine the severity of the seizures, and locate the epileptogenic zone 
(Villanueva et al, 2007). The ictogenic area will be the one dissected from the remaining presumed 
healthy brain tissue. Mapping the epileptic area must be done with care in order to verify which will 
be the important areas that might be involved in resection and, if no impairment is forecasted in the 
dissectible loci, the patient will undergo surgery. Surgery usually reaches 90% of success in healing 
focal epilepsy. Best surgical results are achieved when small epileptic lesions are dissected, but 
improvement in the quality of life in partially successful surgery should also be considered a good 
achievement.   
Intractable epilepsy may also be treated by Vagus Nerve Stimulation (VNS). VNS is an alternative 
treatment for patients refractory to drug therapy and/or in which surgery could not be applied or 
resulted ineffective. Chronic refractory partial and secondarily generalized seizures are examples of 
epileptic syndromes that can be treated by VNS. VNS consists of a stimulating device implanted 
under the skin, which sends electrical impulses to the left side of the vagus nerve in the neck. Its 
mechanism of action is still on debate. Vagus, the tenth cranial nerve, arises from the medulla and 
carries both afferent and efferent fibres. The afferent vagal fibres connect to the nucleus of the 
solitary tract which in turn projects connections to other locations in the central nervous system. 
Little is understood about exactly how vagal nerve stimulation modulates mood and seizure control 
but proposed mechanisms seem related to an increase of thalamic synaptic activity. This effect 
seems to be brought about by release of epinephrine through the nucleus coeruleus and/or 
involvement of nucleus tractus solitarius, the structure that receives the C fibres of the Vagus nerve. 
The nucleus tractus solitarius is related to several areas involved in seizures onset (Milby et al, 2008; 
Ghanem and Early, 2006). Pilot study results demonstrated significant reduction in the frequency, 
intensity, and duration of seizures with chronic, intermittent VNS (Utman et al, 1993; Penry and 
Dean, 1990; Uthman et al, 1990; Wilder et al, 1991; Murphy et al, 1995; Labar et al, 1998). Follow 
up studies report a mean of 50-60% success for VNS when associated to normal pharmacological 
treatment (Ardesch et al, 2007; Abubakr and Wambacq, 2008; Milby et al, 2008). Indeed, patients 
experience a reduction of seizure frequency and duration. VNS seems also to progressively increase 
its effectiveness in seizures containment in time (Ardesch et al, 2007; Milby et al, 2008). Very few 
are the side effects of this practice, comprising hoarseness of voice, cough and sometimes weight 
loss; most of them are very mild and bearable for patients.  
Ketogenic diet represent another side treatment for intractable refractory epilepsy and for epilepsy 
at large. The efficacy of the diet is independent of the type of seizure and is effective for both 
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generalized and partial seizures at varied ages. This therapy is characterized by a diet high in fat and 
low in carbohydrates and protein. In these conditions, energy is retrieved from fatty acid oxidation 
and high concentration of ketone bodies (such as β-hydroxybutyrate, acetoacetate, and acetone) are 
generated. Ketones are then used as nutrients for the body and even for the brain. The use of 
ketones as source of energy in the brain seems to directly or indirectly affect neurotransmitter 
biology leading to a possible, even if yet unknown, mechanism of action. High percentage of good  
outcome is reported for this treatment, also reviewing patients in seizure free conditions of after one 
year of treatment. Recent findings attributed to ketogenic diet a potential effectiveness in preventing 
epileptogenesis (for review see: Bough and Rho, 2007; Freeman et al, 2007; Hartman et al, 2007).  
Avoidance therapy is a therapy applicable only to reflex seizures (see below “classification”). It 
consists in putting patients in the condition to avoid the precipitating phenomenon of their seizures. 
Main precipitating phenomena are related to sensory organs and comprise: music and noise, light 
and dark, touching feelings, tastes and sometimes emotional involvement. This very simple 
approach is usually successful, leading patients to experience very few seizures.   
 
 
Classification 
 
Epilepsy is classified by 5 main criteria: 
o Aetiology (cause of the first seizures)  
o Semiology (manifestation of the seizures) 
o Triggering event(s) 
o Syndromic symptoms 
o Brain anatomic focus-foci (focal/partial or generalized seizures) 
 
Considering aetiology, epilepsy is classified as idiopathic or secondary and probably symptomatic 
(definition preferred to criptogenic in the last revision of the terms). Each of these comprehends 
generalized or partial seizure types (Tab. 2).  
The term idiopathic describes a syndrome that is only epilepsy, with no underlying structural brain 
lesion or other neurological signs or symptoms. These are presumed to be genetic and are usually 
age-dependent (Engel, 2006). Attention must be posed on the correct definition of "idiopathic," 
which means a disorder onto itself, sui generis, and not aetiology unknown.  
Epilepsies described as secondary are related to a known or a suspected disorder of the CNS which 
is the trigger of the symptoms. Known causes of secondary epilepsies are: head traumas, tumors, 
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viral and bacterial encephalopathies, anoxia, etc. The probably symptomatic (formerly cryptogenic) 
epilepsies are referred to epilepsies of unknown nature which are usually suspected to be related to 
a specific disorder of the brain (Engel, 2006).  
The definition of partial (or focal) seizures refers to a specific brain-localized-origin of the seizures. 
Generalized seizures, instead, refers to a general involvement of both brain hemispheres in the 
origin of the seizures.    
  
Table 2: Classification by aetiology of the disease. 
Idiopathic 
Partial seizures type Benign Familiar Epilepsy in Infancy 
Childhood benign epilepsy with central or 
temporal burst 
Childhood benign epilepsy with occipital 
burst 
Other form of idiopathic epilepsy with 
partial seizures 
Generalized seizures type Benign myoclonic epilepsy in infancy 
Childhood absence epilepsy (Pyknolepsy) 
Juvenile myoclonic epilepsy 
Juvenile absence epilepsy 
Generalized epilepsy with tonic-clonic 
seizures 
Secondary and Probably symptomatic 
epilepsy syndrome 
Generalized seizures type Early suppression-burst encephalitis in 
infancy 
West syndrome 
Lennox-Gastaut syndrome 
Progressive epileptogenic encephalitis  
Partial seizures type Severe childhood myoclonic epilepsies 
Mesial temporal epilepsy 
Other epilepsy defined by their focus of 
origin 
 
 
By semiology, epilepsy is classified in self limited seizure types and continuous seizure types and 
each of these are subdivided in generalized and focal seizures (Tab. 3) (Engel, 2006). Self limited 
seizures usually end in a reasonable limit of time; on the contrary, continuous seizures are 
characterized by repetition of the ictal phenomenon for a long period of time with no remission 
between seizures (i.e. status epilepticus).   
 
 
Table 3: Classification by semiology (Epileptic seizure types) 
Se
lf 
lim
ite
d 
se
iz
ur
e 
ty
pe
s 
G
en
er
al
iz
ed
 se
iz
ur
es
 
Tonic-clonic seizures (includes variations 
beginning with a clonic or myoclonic 
phase) 
 
Clonic seizures 
 
Without tonic features 
With tonic features 
Typical absence seizures  
Atypical absence seizures  
Myoclonic absence seizures  
Tonic seizures  
Spasms  
Myoclonic seizures  
Eyelid myoclonia Without absences 
With absences 
Myoclonic atonic seizures  
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Negative myoclonus  
Atonic seizures  
Fo
ca
l s
ei
zu
re
s 
Focal sensory seizures 
 
With elementary sensory symptoms (e.g., occipital and parietal lobe 
seizures) 
With experiential sensory symptoms (e.g., temporo parieto occipital 
junction seizures) 
Focal motor seizures 
 
With elementary clonic motor signs 
With asymmetrical tonic motor seizures (e.g., supplementary motor 
seizures) 
With typical (temporal lobe) automatisms (e.g., mesial temporal lobe 
seizures) 
With hyperkinetic automatisms 
With focal negative myoclonus 
With inhibitory motor seizures 
Gelastic seizures  
Hemiclonic seizures  
Secondarily generalized seizures  
C
on
tin
uo
us
 se
iz
ur
e 
ty
pe
s 
G
en
er
al
iz
ed
 
st
at
us
 e
pi
le
pt
ic
us
 
 
Generalized tonic-clonic status 
epilepticus 
 
Clonic status epilepticus  
Absence status epilepticus  
Tonic status epilepticus  
Myoclonic status epilepticus  
Fo
ca
l s
ta
tu
s 
ep
ile
pt
ic
us
 
Epilepsia partialis continua of 
Kojevnikov 
 
Aura continua  
Limbic status epilepticus (psychomotor 
status) 
 
Hemiconvulsive status  
Adapted from Engel (2001) with permission. 
 
By definition, a reflex epilepsy syndrome is a syndrome in which all epileptic seizures are 
precipitated by sensory stimuli. Reflex seizures that occur in focal and generalized epilepsy 
syndromes that are also associated with spontaneous seizures are listed on the basis of seizure types. 
Isolated reflex seizures can also occur in situations that do not necessarily require a diagnosis of 
epilepsy. Seizures precipitated by other special circumstances, such as fever or alcohol withdrawal, 
are not reflex seizures (Engel, 2006). Principal stimuli considered as precipitating circumstances of 
reflex epilepsy syndromes are reported in Tab. 4. 
 
Table 4: Precipitating stimuli for reflex seizures 
Pr
ec
ip
ita
tin
g 
st
im
ul
i f
or
 re
fle
x 
se
iz
ur
es
 
Visual stimuli 
 
Flickering light: color to be specified 
when possible 
Patterns 
Other visual stimuli 
Thinking  
Music  
Eating  
Praxis  
Somatosensory  
Proprioceptive  
Reading  
Hot water  
Startle  
Adapted from Engel (2001) with permission. 
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An epilepsy syndrome is a complex of signs and symptoms that define a unique epilepsy condition 
with different aetiologies (Engel, 2006). This must involve more characteristics than just the seizure 
type such as: age of onset, progressive nature, interictal EEG, associated interictal signs and 
symptoms, pathophysiologic mechanisms, anatomic substrates, etiological categories and genetic 
basis (Engel, 2006). The different syndromes are summarized in Tab. 5. In this table are also 
reported syndrome conditions which, by their nature, must not be considered as epilepsy but as 
convulsive episodes.  
Classification of epileptic syndromes is a difficult matter, considering that a full description of each 
syndrome is sometimes far from being complete and, for some of them, only a few characteristics 
have been reported. Including an epilepsy syndrome in an official classification gives it the status of 
a recognized syndrome. On the other hand, excluding poorly described syndromes from an accepted 
classification could lead to a reduced investigation in that direction, failing to uncover important 
features of scarcely reported syndromes (Engel, 2001). For these reasons the reported table has 
signalled few syndromes as in definition development.  
Another important case is raised by syndromes of Idiopathic Generalized Epilepsy (IGE), only eight 
of which are recognized by ILAE (Nordli, 2005), even if other are described in the literature 
(Panayiotopoulos, 2005). The difficulties stem from the practical view that IGE are clinically 
considered as one disease, leading to an easy clinical approach, but in reality IGE comprise several 
syndromes. This would imply to consider IGE as a complex ensemble of different syndromes which 
would be more demanding diagnostically. Therefore, in view of a better differential diagnosis, a 
well organized classification of epilepsy syndromes would be a useful tool for the physicians.  
 
Table 5: Epilepsy syndromes and related conditions 
Benign familial neonatal seizures   
Early myoclonic encephalopathy   
Ohtahara syndrome   
aMigrating partial seizures of infancy   
West syndrome   
Benign myoclonic epilepsy in infancy   
Benign familial infantile seizures   
Benign infantile seizures (non-familial)   
Dravet’s syndrome   
HHE syndrome   
aMyoclonic status in non-progressive 
encephalopathies 
  
Benign childhood epilepsy with centrotemporal 
spikes 
  
Early onset benign childhood occipital epilepsy 
(Panayiotopoulos type) 
  
Late onset childhood occipital epilepsy (Gastaut 
type) 
  
Epilepsy with myoclonic absences   
Lennox–Gastaut syndrome   
Landau–Kleffner syndrome   
Epilepsy with continuous spike-and-waves during 
slow-wave sleep (other than LKS) 
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Progressive myoclonus epilepsies 
 
  
Idiopathic generalized epilepsies with variable 
phenotypes 
Juvenile absence epilepsy  
Juvenile myoclonic epilepsy  
Epilepsy with generalized tonic-clonic 
seizures only 
 
Reflex epilepsies 
 
Idiopathic photosensitive occipital lobe 
epilepsy 
 
Other visual sensitive epilepsies  
Primary reading epilepsy  
Startle epilepsy  
Autosomal dominant nocturnal frontal lobe 
epilepsy 
  
Familial temporal lobe epilepsies   
aGeneralized epilepsies with febrile seizures plus   
aFamilial focal epilepsy with variable foci   
Symptomatic (or probably symptomatic) focal 
epilepsies 
Limbic epilepsies 
 
Mesial temporal lobe 
epilepsy with hippocampal 
sclerosis 
Mesial temporal lobe 
epilepsy defined by specific 
etiologies 
Other types defined by 
location and etiology 
Neocortical epilepsies 
 
Rasmussen syndrome 
Other types defined by 
location and etiology 
Conditions with epileptic seizures that do not 
require a diagnosis of epilepsy 
 
Benign neonatal seizures  
Febrile seizures  
Reflex seizures  
Alcohol-withdrawal seizures  
Drug or other chemically induced seizures  
Immediate and early post cerebral insult 
seizures 
 
Single seizures or isolated clusters of seizures  
Rarely repeated seizures (oligoepilepsy)  
Adapted from Engel (2001) with permission. (a Syndromes in development) 
 
 
Models of epilepsy 
(For en extensive review of epilepsy modelling see “Models of seizures and epilepsy” Pitkanen A., Schwartzkroin P.A. 
and Moshé S.L. (2006) Elsevier Academic Press) 
 
The study of epilepsy can not be performed only in humans because of several different reasons, 
from ethical issues to practical inapplicability, from unavailability of controls to high costs of 
human research. For all these reasons, modelling epilepsy is of a central importance. Epilepsy 
models for studying epilepsy are principally used for three reasons:  
1. to understand basic mechanisms underlying the pathology; 
2. to devise new approaches for diagnosis; 
3. to test new drugs or new therapies. 
Basic mechanisms of epilepsy are still under strong investigation and epileptic models are a very 
precious tool to deeply understand the molecular and physiological causes of this complex 
pathology. Of course, uncovering the mechanisms underpinning the disease will help develop new 
diagnostic, therapeutic and preventive approaches. Models of epilepsy are the best instruments on 
 19
which innovative experimental approaches for diagnosis and therapies can be tested. This will speed 
up the application of new diagnostic and therapeutic tools, allowing rapid intervention on the 
disease. In each of these cases, human studies can give a big support, but preliminary data are 
normally retrieved from in vitro and in vivo experiments. 
Epilepsy models should be created or prepared in order to faithfully reproduce the human epileptic 
condition. Therefore several different models have been developed trying to model all the complex 
aspects of this pathology. On the other hand, some experimental approaches model only some of the 
manifestation of epilepsy (epilepsy equivalent) allowing only the investigation on that symptom and 
not on the whole complex picture of a complete model. In any case, this gives the chance to study 
an aspect of the disease.  
Therefore, the already reported epidemiology that describes 1% of the population as affected from 
some kind of epilepsy, which in turn explains the economic, social and personal cost of the disease, 
makes it clear how important is to study epilepsy and how important are the tools that model it.      
 
Induced models of epilepsy 
Induced models of epilepsy are developed by application of chemical, electrical or damaging insults 
on a healthy brain, in order to transform that brain in an ill one, capable to show features of the 
chosen kind of epilepsy in study. 
 
Table 6: Induced model of epilepsy (classification based on the tools used to develop the models). 
In
 V
itr
o 
Cell culture Models   
Acute and organotypic slices   
Single nerve cells acutely 
dissociated from animal and 
human brain  
  
In vitro isolated guinea pig 
brain   
In
 V
iv
o 
chemical model of epilepsy 
GABA 
Pentylenetetrazole  
Bicuculline 
Picrotoxin 
Glutamic Acid Decarboxylase (GAD) 
inhibitors 
Beta carbolines and convulsant 
benzodiazepine Ro 5-3663 
GHB (gamma-hydroxy-butyrate)  
Excitatory Amino-Acid 
Kainic acid  
Quisqualic acid/alfa-amino-3-Hydroxy-5-
Methyl-4-Isoxasole Propionic acid 
N-Methyl-D-Aspartic acid (NMDA) 
Homocysteine, homocysteic acid 
Acetylcholine related substances Pilocarpine, and litium-pilocarpine Organophosphorus compounds 
Other drugs 
Strycnine 
Aminophylline 
Insulin induced hypoglycemia 
Ay-9944  
THIP (4,5,6,7 tetrahydroxyisoxazolo 
(4,5,c) pyridine 3-ol)  
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Inhalants Fluorothyl 
Topical application 
Metals (cobalt, zinc, antimony, alumina 
cream, iron 
Antibiotic (penicillins and cephalosporins) 
Tetanus toxin 
electrical model of epilepsy 
electroshock seizures  
local electrical stimulation  
electrical kindling  
self sustaining status epilepticus by 
Perforant Path stimulation  
self sustaining status epilepticus by 
Amygdala stimulation  
focal status epilepticus  by perforant 
path stimulation in anesthetized rats  
continuous hippocampal stimulation  
lesion model of epilepsy 
cortical freeze lesion model  
antiproliferative agents (5-azacytidine, 
methyl-mercury, nitrosureas and 
carmustine) 
 
Methylazoxymethanol acetate (MAM) 
model  
In-Utero irradiation as a model of 
cortical dysplasia  
Hypoxia-induced seizures and hypoxic 
encephalopathy in neonatal period  
Lateral fluid percussion brain injury  
Chronic Partial Cortical Isolation 
model  
Head Trauma: haemorrhage-Iron 
Deposit  
Stroke  
Others 
Complex febrile seizures – 
experimental model in immature 
rodents 
 
Infection induced seizures Model of neurocysticercosis 
 Model of herpes virus infection 
Rasmussen’s encephalitis model  
 
 
Genetic models of epilepsy 
The above reported epilepsy models are related to chemically, electrically or mechanically induced 
alterations in an otherwise healthy brain. Genetic models of epilepsy, instead, refer to a molecularly 
and/or anatomically altered brain due to genetic alterations. These models can be naturally selected 
in animals spontaneously showing epilepsy phenomena or can be created by introducing gene 
mutations. Either ways, animals show and model a particular kind of epilepsy. On one hand, a 
naturally occurring seizure behaviour in a spontaneously epileptic animal (i.e. GAERS and 
WAG/Rij  for rats and tottering, lethargic, ducky, stargazer etc for mice); on the other hand, specific 
seizures and syndromes induced by targeted alteration of genes already known to cause or to be 
involved in a particular type of epilepsy. Table 7 and 8 reports spontaneous and induced genetic 
models. 
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Table 7: Spontaneous models of epilepsy 
rats Absence model  
GAERS rats 
WAG/Rij rats 
mice 
Spike wave 
Tottering 
lethargic 
ducky 
stargazer 
SWE 
Mocha2j 
coloboma 
convulsion 
Dilute lethal 
jimpy 
jittery 
megencephaly 
quaking 
staggerer 
torpid 
veritint waddler 
wabbler-lethal 
weaver 
writher 
convulsions evoked by sensory stimuli frings 
 lurcher 
 
Table 8: Induced model of seizures 
Gene involved Protein modified 
NPY Neuropeptide Y 
Syn1 Synapsin 1 
Syn2 Synapsin 2 
Slc1a (Glt-1) Glutamate transporter 
Akp2 Tissue nonspecific alcaline phosphatase (GABA syntesis) 
Gad2 Glutamic acid decarboxylase (GABA synthesis) 
Gabrβ3 GABAA receptor β3 subunit 
Gabrδ GABAA receptor δ subunit 
Gria2 Glutamate receptor subunit 2 
Htr2c Hydroxytryptamine receptor 2c 
Kcna1 Voltage-gated K+ channel 
Scn2a Sodium channel type 2a (brain specific) 
Kcnj6 (Girk2) Inwardly rectifying K+ channel 
Camka Calcium calmodulin kinase α subunit 
Itpr1 Inositol 1,4,5 trisphosphate receptor 
Gap43 Growth-associated protein 
Cdk5r Neuronal-specific activator of cyclin kinase 
Otx1 Orthodenticle homolog (homeobox family) 
Jrk Jerky (DNA-binding protein) 
Pcmt1 Protein L-isoaspartate (D-aspartate) O.methyltransferase (protein repair enzyme) 
Hex-a α subunit of β-hexosaminidase (lysosomal enzyme) 
Hex-b β subunit of β-hexosaminidase (lysosomal enzyme) 
Stfb (Cstb) Cystatin-B (cysteine protease inhibitor) 
Psap Sphingolipid activator protein 
Il6 Cytokine, interleukin 6 
App Amyloid precursor protein 
Hdh Huntingtin’s amino-terminal polyglutamine sequence 
Polyglutamine repeat 146 unit CAG repeat inserted in hprt gene 
Bdnf (homozygous) BDNF 
Fyn Tyrosine kinase receptor 
Plat Tissue plasminogen activator 
Fos Protooncogene 
Mt-3 Metallothionein-3 
… … 
Others Many others are already available and several others will be modelled as soon as new 
genes will be found responsible for an epileptic syndrome.  
Modified From Puranam and McNamara, 1999 
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GENES AND EPILEPSY 
 
 
Of the about 1% of the population affected by epilepsy, 30-40% are estimated to have a genetic 
contribution to the aetiology (Gardiner, 2000; Berkovic et al, 2006). Indeed, among all the 
classifications for epilepsy, one consistent group is represented by the idiopathic epilepsies which 
are usually described as epilepsies with no known causes and, therefore, probably genetic. 
Epidemiologic studies describe also the risk of hereditary transmission of epilepsy from parents 
experiencing epilepsy or having familiarity for this pathology (Winawer and Shinnar, 2005). Beside 
a general risk of 5‰ of children born with epilepsy in the general population, there is an increased 
risk of seizures in siblings and offspring of pro-bands with the epileptic pathology. This is mainly 
related to parent gender with a maternal higher effect (Ottman et al, 1988), early age at onset 
(Anderson and Hauser, 1997; Ottman et al, 1996a), number and closeness of affected relatives 
(Winawer and Shinnar, 2005) and EEG abnormalities including generalized spike waves and 
photoparoxysmal response (Anderson and Hauser, 1997). Parents affected by idiopathic epilepsies 
have higher risk to transmit epilepsy than parents affected by symptomatic ones. Hereditary risks 
depend also from the different seizure types affecting the pro-bands: parents with myoclonic and 
absence seizures as well as with generalized seizures have higher risk to transmit epilepsy to 
offspring than people experiencing partial seizures (Eisner et al, 1959; Tsuboi and Christian, 1973; 
Tsuboi, 1980; Annegers et al, 1982; Beck-Mannagetta and Janz, 1991; Ottman et al, 1998; Ottman 
et al, 1989).  In any event, the data are reassuring; more than 90% of individuals with epilepsy have 
no affected relatives, and most parents with epilepsy will have no children with epilepsy. In 
conclusion, the general genetic risk of epilepsy transmission is about 5% for parents having a direct 
or indirect history of epilepsy (Winawer and Shinnar, 2005).   
 
Genetic epilepsies can be classified based on the mechanism of inheritance in (Gardiner, 2000): 
o Mendelian disorders; 
o Non-Mendelian disorders or complex epilepsies; 
o Chromosomal disorders. 
 
Mendelian disorders are those in which one single major locus represents the main genetic 
modification which is responsible for the epileptic phenotype. Modes of inheritance are the 
common autosomal dominant, autosomal recessive, X-linked dominant and X-linked recessive. 
Primary Mendelian epilepsies are considered rare and account only for 1% of the genetic epilepsies. 
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However, they form an important group because recognition of the characteristic features and 
presence of a family history enables the correct diagnosis to be made. In these disorders single gene 
mutation leads to a deleterious change in gene sequence, presumably bringing to either loss of the 
encoded protein function or gain of function mutation. Either way, a disruption of the pathway 
including the modified protein is affected, exacerbating the epileptic phenotype.  Examples of these 
diseases are: Benign Familial Neonatal Convulsion (EBN1, EBN2); Autosomal Dominant 
Nocturnal Frontal Lobe Epilepsy (ADNFLE); Generalized Epilepsy with Febrile Seizures Plus 
(GEFS+). Several times, epilepsy is one of the major symptoms of Mendelian transmitted disorders 
such as Unverricht-Lundborg disease, Lafora Disease or Fragile X syndrome. 
Non Mendelian disorders (complex epilepsies) are characterized by a complex inheritance and 
represent about 70% of the idiopathic epilepsies (Anneger, 1996). They are usually polygenic, as 
suggested by rapidly diminishing risks beyond first-degree relatives (Ottman et al, 1996b) and high 
concordance between monozygotic twins (Berkovic et al, 1998). Mechanisms of inheritance for 
these diseases showed a complex pattern and not only one gene is presumed to be involved. 
Complex epilepsy arises when, by chance, meiotic reshuffling creates a combination of 
susceptibility alleles with sufficient effect in the same individual to push neuronal hyperexcitability 
over the seizure threshold. Each susceptibility allele alone is insufficient to cause seizures, but 
requires the additive or epistatic interaction of other susceptibility alleles. Complex epilepsy is most 
often expressed sporadically in an affected individual, and the phenotype does not follow 
Mendelian inheritance. Nor do the close relatives, who may or may not be affected, necessarily 
share the same set of epilepsy susceptibility alleles. During intergeneration transmission, each 
susceptibility allele is segregated away from other unlinked susceptibility alleles (Mulley et al, 
2005). This group of genetic epilepsies include Juvenile Myoclonic Epilepsy (JME), Childhood 
Absence Epilepsy (CAE) and Benign Childhood Epilepsy with Centrotemporal Spikes (BCECTS) 
(Mulley et al, 2005).  
Chromosomal disorders associate to epilepsy many times, as happens in Down Syndrome (trisomy 
21p), in trisomy 12p, in trysomy 1q42.3-qter (Tuschl K et al, 2007), monosomy 21q22.3-qter 
(Tuschl K et al, 2007), etc. They are usually related to a gross cytogenetic abnormality which 
ordinarily determine a syndrome in which epilepsy may be an important component.   
 
Genetic epilepsy can be also classified based on functional classification as follows (Noebels, 2003):  
o those linked to primary defects of membrane and synaptic signalling, 
o those linked to neuronal plasticity and metabolism, 
o those linked to network development. 
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Epilepsies of the first group are characterized by genetic alterations that modify general 
neurotransmission leading to an imbalance between excitatory and inhibitory stimuli that exacerbate 
epileptic phenomena. Among those classified in this group, a large number is represented by 
mutations in neuronal ion channels, the so called channelopathies. Channelopathies have been 
among the first disorders associated to genetic modifications in epilepsy and gave a boost for a 
deeper investigation of the genetics of epilepsy.  
Impaired neuronal ion channel function has been associated to several pathologies like 
neuromuscular disorders (Bernard and shevell, 2008), chronic pain (Catterall et al, 2008), migraine 
(Catterall et al, 2008) and epilepsy (Noebels, 2003; Heron et al, 2007; Bernard and Shevell, 2008, 
Catterell et al, 2008). Symptoms of a channelopathy may present either as an abnormal gain of 
function or as a loss of function of the channel affected by the mutation. Channelopathies usually 
demonstrate both phenotypic and genetic heterogeneity. Phenotypic heterogeneity means that 
different mutations in the same gene can cause different diseases. Genetic heterogeneity means that 
mutations in different genes can result in the same apparent disease phenotype (Bernard and Shevell, 
2008). 
Numerous are the genetic epilepsies caused by channelopathies, including Autosomal Dominant 
Nocturnal Frontal Lobe Epilepsy (ADNFLE), caused by mutation in the acetylcholine receptor 
subunit alfa-4 or subunit alfa-2, Generalized Epilepsy with Febrile Seizures plus (GEFS+) caused 
by mutation on sodium channel alfa-1 and beta-1 subunit or on GABA-A receptor gamma-2 subunit, 
Benign Familial Neonatal Seizures (BFNS) due to mutations on potassium channel subunits. 
Epileptic channelopaties present normally as monogenic inherited alterations (Heron et al, 2007) 
even though they may associate to complex patterns of inheritance involving more than one 
mutation to exacerbate the epileptic phenotype (Mulley et al, 2005; Heron et al, 2007).  
Synaptic signalling may be disrupted and cause epilepsy also by mutations involving the large 
protein families that mediate vesicle trafficking and exocytosis (Bock et al, 2001). Seizures appear 
in mice deleted for the vesicle-anchoring phosphoproteins synapsins 1 and 2; loss of these proteins 
diminishes the size of the presynaptic vesicle pool and disrupts synaptic depression (Rosahl et al. 
1995).  
Another synaptic vesicle protein, Sv2A, also regulates synaptic strength by altering the mobility of 
the releasable pool. Sv2A-deficient mice, alone or combined with Sv2B nulls, show a severe seizure 
phenotype (Crowder et al. 1999, Janz et al. 1999). In contrast to synapsin mutants, neurons showed 
sustained release of transmitter in response to brief activation.  
At an earlier stage in vesicle biogenesis, incomplete vesicle assembly can also lead to an epileptic 
phenotype. The mocha mouse encodes the AP3-delta subunit of an adaptor complex that facilitates 
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incorporation of the Znt3 zinc transporter into synaptic vesicles. Lack of the delta subunit leads to 
loss of vesicular zinc sequestration, severe EEG hypersychronization, and seizures (Kantheti et al. 
1998). 
In conclusion, all the mutations affecting neurotransmission may lead to an imbalance of 
excitatory/inhibitory signalling leading to hyperexcitability, which in turn may manifest as epileptic 
seizures. 
Epilepsy can be observed during the course of many inborn errors of metabolism (IEMs), usually as 
part of a large clinical spectrum, and several IEMs may manifest with inaugural epileptic seizures 
(Sedel et al, 2007). These diseases may be subdivided according to the type of clinical presentations 
into progressive myoclonic epilepsies, epileptic seizures without mental retardation, epilepsies with 
mental retardation. In the first group are worth to be mentioned ceroid lipofuscinosis, sialidosis, and 
lafora disease. The second group includes Wilson disease and acute neuropsychiatric porphyries. 
The last group comprises De Vivo disease, creatine synthesis or transport defects and succinic 
semialdehyde dehydrogenase. All these disorders are characterized by altered metabolic pathways 
in which a known protein has been found as the putative responsible for the disease. Unfortunately, 
the molecular functions of the different proteins remain to be elucidated in most of the diseases and, 
in many cases, studies are required to better understand the link between protein mutation and 
epileptic manifestations.   
The third group of the functional classification reported above is represented by epilepsies in which 
the genetic mutation leads to altered cyto-architectonic formation of brain structures. Cortical 
dysplasias resulting from aberrant patterns of brain development are a frequent substrate for 
inherited seizure syndromes. The malformations may be microscopic or visible by magnetic 
resonance imaging and originate from diverse signalling defects affecting migration, proliferation, 
differentiation, and segmentation. For example, defective proliferation and cell dimension have 
been associated to deletion of NeuroD/Beta2, a neuronal transcription factor that selectively blocks 
postnatal proliferation of granule cells in the dentate gyrus. These mice show a hippocampal 
formation entirely devoid of a granule cell layer, but with a preserved pyramidal cell layer and theta 
rhythm generation, and exhibit frequent partial motor seizures in adulthood (Liu et al. 2000). The 
same hippocampal phenotype is associated to a deletion of citron-kinase (citron-K), a Rho effector 
regulating cytokinesis (Di Cunto et al. 2000). Citron-K-deficient mice lack granule cells and 
develop fatal seizures before adulthood. Disturbance of cell migration has been linked to mutation 
of DCX (Kizhatil et al, 2002), the gene encoding for doublecortin, which leads to subcortical band 
heterotopia syndrome (Feng and Walsh, 2001) comprehensive of seizure phenomena. 
Periventricular nodular heterotopia has been suggested as consequence of a mutation in the filamin 
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gene (FLN1) that interacts with F-actin during motility-related cytoskeletal reorganization, and 
mutation results in a subset of neurons clustered at the ventricular zone. Analysis of mutant human 
FLN1 neurons and chemically induced heterotopias confirms that key intrinsic excitability changes 
occur when cells develop outside of their natural lamination pattern; such molecular rearrangements 
may provoke specific patterns of aberrant receptor expression and loss of repolarizing K+ currents 
that favor epilepsy (Castro et al. 2001, Battaglia et al. 2002). Mutations in the human reelin gene 
(RELN) are linked to a lissencephalic cortical neuronal migration defect with seizures (Hong et al. 
2000). Finally, genetic disruption of homeobox genes related to specification, regionalization, and 
terminal differentiation of the neocortex results in epileptic phenotypes. Example for this are 
deletion for OTX-1 and mutation of ARX.  
Transcription factors and protein silencers act together to control the activation and repression of 
the genetic differentiation program (Robertson and Wolffe 2000). Mutation of genes acting in this 
pathway are now linked to epilepsy. In this group, two mutations are worth to be mentioned: 
mutation of the MECP2 gene associated to Rett Syndrome, an X-linked disorder including mental 
retardation and seizures (Shabazaian et al, 2002; Johnston et al, 2001; Tudor et al, 2002); and 
deletion of jerky gene, which leads to a limbic seizure phenotype in mice, through a putative defect 
in translational processing (Liu et al. 2002). A mutation in the human homologue, JH8, has been 
identified in a case of childhood absence epilepsy (Moore et al. 2001).   
 
Epilepsy is therefore well known as a complex neurological disorder and it is now quite clear that a 
number of human epilepsy syndromes can result from gene mutations (Crino, 2007). Particular gene 
mutations may account also for many epilepsy phenotypes that show little if any evidence for 
inheritance patterns. This may be due to a de-novo mutation. Indeed, one fascinating possibility is 
that sporadic epilepsies result from somatic mutations occurring in brain progenitor cells, which are 
not present in the germline DNA (Crino, 2005; Weiss, 2005). Thus, while sporadic epilepsies might 
not follow Mendelian inheritance patterns, they are nonetheless the result of a genetic or mutational 
event. In this scenario, a deleterious gene mutation might occur during the many rounds of cellular 
mitosis occurring throughout the course of brain development. Moreover, a corollary hypothesis is 
that an accumulation of mutations in a variety of distinct genes, insufficient alone to cause seizures, 
could lead to neuronal hyperexcitability. Thus, somatic mutations in multiple genes during brain 
development might lead to seizure onset. 
This mechanism may provide a further explanation for complex epilepsies (Crino, 2007). 
Considering these possibilities, the genomics approach is important for the possible explanation of 
idiopathic epilepsies. In this respect, single nucleotide polymorphism (SNPs) may play an important 
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role in the onset of several epileptic manifestations. SNPs represent single basepair changes that are 
present in more than 1% of the general population and may be synonymous, with no changes in 
amino-acid in the primary structure of the protein or non-synonymous with amino-acid substitution. 
In non-synonymous SNPs an altered protein function may be expected and may have functional 
consequences in terms of excitability or seizure susceptibility. Following this reasoning, clearly 
results that SNPs relevant to epilepsy occur throughout the genome and thus that subtle alterations 
in basepair sequence in a set number of candidate genes can culminate in an epilepsy phenotype. 
This so-called “common variant-common allele” phenomenon suggests that certain types of 
epilepsy result from an inherent predisposition or predilection based on the unique or additive 
effects of SNPs within a single or multiple genes (Ottman, 2001; Ottman, 2005). Thus, epilepsy 
may reflect a “SNP dose effect” in which seizure susceptibility is directly related to the number and 
functional significance of relevant SNPs throughout the individual genome. Genomic influences 
may account for the majority of patients with no obvious structural or inherited etiology for their 
seizures, so-called idiopathic epilepsy.  
SNP variations may also account for some forms of symptomatic epilepsy. This notion has practical 
importance since it may account for the incidence of seizures in some, but not all, patients with 
tumors, stroke, trauma and so on. For example, even in the setting of brain injury, cortical 
malformation, or tumor, only a proportion of patients will develop epilepsy. It is conceivable that 
these individuals develop seizures not just because of injury to the cortex but rather because of 
combinatorial effects of a brain lesion plus a particular set of predispositional SNPs (Crino, 2007).  
This point of view opens a discussion on how the genetic background may influence epilepsy onset. 
Therefore, the so called modifier genes may account for synergistic or antagonistic interactions with 
known epilepsy susceptibility loci (Durner et al., 2001; for review, see Mulley et al., 2003). These 
sites in the genome, while not directly responsible for seizures, can affect the impact of gene 
mutations or sequence alterations that culminate in seizures. Modifier genes may affect the epilepsy 
phenotype in idiopathic epilepsies and this is well documented by the fact that, in mice, strain 
backgrounds can determine seizure onset in the setting of an engineered gene defect. Moreover, in 
humans, variable expressivity among family members is a common feature of inherited epilepsy 
syndrome of most types, suggesting that genetic modifiers may influence the clinical manifestation 
of epilepsy. 
In the same frame, the genetic background may be responsible for epilepsy onset in symptomatic 
epilepsies. The idea that genes and acquired factors (traumas, injuries, etc.) interact in human 
epilepsies is an old one, dating back to Lennox, in the mid-20th century (Lennox, 1951), and is 
generally accepted for any complex disorder. In this respect, what is thought plausible is that after a 
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brain damaging event, reparation of the injury may activate mechanisms that enhance hyper-
excitability of the damaged areas, which in turn may allow exacerbation of seizures. This relates to 
the influence of the background by the fact that, in the presence of the same damaging event, not all 
patients develops seizures over time. This points out how susceptibility loci created by the injury 
associate to the genetic predisposition to seizures in triggering epileptic phenomena. 
 
Genes and their protein products are also related to epilepsy as a consequence of the seizures. Gene 
expression is perhaps one of the first studied aspects of gene involvement in epilepsy. Indeed 
several studies report altered gene expression in the brain experiencing seizures (Aronica and 
Gorter, 2007; Elliot and Lowenstein, 2004; Likasiuk and Pitkanen, 2004; Lukasiuk et al, 2006; 
Majores et al, 2004; Morgan et al., 1987; Gall et al., 1991; Newton et al., 2003). The modified gene 
expression correlates to pathophysiology in all the possible ways, either in a protective attempt to 
prevent seizures to happen again or, in an aberrant acting fashion, leading to a worsening of the 
disease. From a mechanistic perspective, it is tacitly assumed that altered mRNA levels predict 
similar changes in functional protein expression that disrupt normal cell function, although this 
relationship is not universal. Seizure-induced changes in mRNA expression are usually associated 
with long-lasting changes in protein expression that have functional relevance in terms of cellular 
architecture, network reorganization, cell proliferation, cell death, and perhaps most interesting, 
fostering recurrent seizures. Under a certain point of view, the “holy grail” of gene expression 
analysis studies in epilepsy has been to define either a single gene or a panel of genes that are the 
first steps in the epileptogenesis cascade. This mainly in relation to the fact that symptomatic 
epilepsies are usually a consequence of a plastic modification occurring after a damaging event that 
may lead to the manifestation of recurrent seizures. Deep investigation in gene expression put in 
motion during epileptic events may shed light on the putative starters of the neuronal plasticity 
which at a certain point may exacerbate in epileptic phenomena. The therapeutic implications of 
these essential genes are numerous. 
 
Finally, it is important to stress how difficult is to associate genetic defects to an epileptic syndrome. 
Very few genetic associations for idiopathic epilepsy have been replicated and this has tempered 
enthusiasm for the results of genetic studies in epilepsy. Failure to replicate is most often attributed 
to multiple testing, type I error considerations (i.e., the belief that the original finding was a false 
positive) (Tan et al., 2004), population stratification, sample size (Tan et al., 2004; Durner et al., 
2006), and genetic heterogeneity (Pal et al, 2008). The main concepts to keep in mind while trying 
to evaluate a putative gene modification attributable to a idiopathic epilepsy must be independent 
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replication of the gene association and coherence of evidence. Indeed, independent replication of 
association is an important criterion in judging evidence, yet the absence of replication may not 
necessarily invalidate an original finding. Therefore, it has been suggested to adopt a perspective 
integrating results from different experimental methods, rather than place one over another in 
importance or insisting only on replication. Coherence of experimental methods is a more 
informative approach than simple replication, because it forces one to evaluate different kinds of 
experimental data in the context of findings from other approaches. 
 
Concluding, the last few decades have seen an increasing number of reports on the genetic basis of 
idiopathic epilepsies and on the involvement of genetics and gene expression in epileptic 
phenomena, confirming that genes and their protein products play a pivotal role in defining the 
outcome of the disease and the subtle differences in epileptic manifestations. Therefore, 
comprehension of the complex genetic mechanisms underlying epileptogenesis may allow a better 
understanding of the pathology and may help define new therapeutic targets.   
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GENERAL AIMS OF THE STUDY  
AND THESIS STRUCTURE 
 
 
The overall aim of this thesis has been to characterize three different genetic modifications that are 
directly or indirectly related to epilepsy, in an attempt to shed light on diverse genetic mechanisms 
leading to diverse epilepsy types or to susceptibility to seizures. These three different genetic 
mutations have been investigated under different points of view, with the common goal of 
increasing knowledge of the mechanisms by which they may eventually lead to the pathology.  
Data have been organized in separate chapters: 
1. the first chapter deals with a primary genetic epileptic syndrome, the Unverricht-Lundborg 
disease, and leads to the proposal of a pathogenetic mechanism for its onset and progression; 
2. the second chapter deals with Fragile X mental retardation, a genetic disease that associates 
with epileptic seizures in 20-25% of the cases, and focuses on the study of the subcellular 
targeting of the gene product whose silencing causes Fragile X (FMRP);  
3. in the last chapter, we investigated a putative susceptibility gene, the bradykinin B1 receptor 
gene, by studying the susceptibility to seizures of B1 knockout mice in two different models 
of epilepsy. 
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Chapter II 
 
Unverricht-Lundborg disease 
a mouse model for CSTB deficiency 
 
 
(this chapter is based on the paper Franceschetti et al, 2007) 
(work have been conducted in collaboration with the Institute C. Besta in Milan with Prof Franceschetti Silvana and collaborators)
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INTRODUCTION 
 
Myoclonus 
 
Myoclonus is a brief, sudden and involuntary movement of a muscle or a group of muscles. It is 
defined as positive myoclonus when active muscle contraction is involved, and negative when an 
inhibitory muscle stimulus underpins the phenomenon. It can present  as a single myoclonus or a 
group of subsequent muscle movements and may develop casually or following a precise scheme. 
Myoclonus usually arises from brain alterations involving cortical, sub-cortical and spinal cord 
areas. It can be benign, as it is hiccups (a myoclonus of the diaphragm), or represent a symptom in 
different pathologies: multiple sclerosis, Parkinson disease, Alzheimer disease, Creutzfeldt-Jakob 
disease, epilepsy.  
ILAE (International League Against Epilepsy) defined 4 different main kinds of myoclonus: 
1. Cortical myoclonus (CM): CM is due to hyperexcitability of the sensorimotor cortex, and 
each muscle jerk results from a neuronal discharge in the sensorimotor cortex. 
2. Thalamocortical myoclonus: in thalamocortical myoclonus a thalamocortical loop is 
involved. In both instances, CM and thalamocortical myoclonus conduction velocity from 
cortex to muscles is fast: -60 m/s. Timing of muscle innervation after a cortical discharge 
shows a rostrocaudal lag, with muscles innervated by first cranial nerves contracting initially 
and those innervated by last cranial nerves contracting later. CM combines a brief (20-75 ms) 
contraction of both agonist and antagonist muscles. 
3. Reticular reflex myoclonus (RRM): RRM results from hyperexcitability of the caudal 
reticular formation. In contrast to those in CM, electromyographic (EMG) events reflect 
sequential innervation, with the ninth, seventh and then fifth cranial nerves innervated in 
that order. Muscle jerks, which last 80-330 ms, precede cortical events. RRM may affect a 
single muscle or both agonist and antagonist muscles, with proximal muscles often affected, 
usually bilaterally. 
4. Negative myoclonus (NM):  NM consists of the inhibition of muscular activity and can be 
demonstrated as lapses interrupting previously continuous muscular activity when the 
patient is maintaining a posture. 
In terms of bodily involvement, myoclonus and myoclonic seizures may be focal (i.e. confined to 
one region), regional (i.e. affecting two or more contiguous regions) or generalized involving the 
whole body. They differ from tonic-clonic seizures in that are of much shorter duration and involve 
much less movement.  In terms of timing, myoclonic seizures can consist of single jerk or repetitive 
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jerks. Myoclonic seizures may also be rhythmic or arrhythmic. In terms of amplitude, they can be 
small (e.g. no joint movement) or massive contractions (e.g. movement of extremities, trunk and/or 
head). To further complicate their classification, myclonic seizures can occur unilaterally or 
bilaterally and, if bilaterally, symmetrically or asymmetrically (Leppik, 2003). 
 
A myoclonus is termed epileptic when it occurs in combination with cortical epileptiform 
discharges, and as illustrated by ILAE epileptic myoclonus should be distinguished from the 
following conditions: 
o Non-myoclonic epileptic seizures, including spasms, which are more prolonged, occur in 
clusters, and are combined with a high-amplitude EEG slow wave. They should also be 
distinguished from tonic seizures, which are associated with EEG low amplitude fast 
activity; 
o Non-epileptic myoclonus, including opsoclonus myoclonus syndrome, sleep myoclonus and 
progressive distonya; 
o Non-epileptic, non-myoclonic phenomena, particular tremor in which the contraction affects 
agonist and antagonist muscles alternatively and is more rhythmic than myoclonus. 
Examples may be TICs and Chorea. 
 
Electrophysiological criteria for differentiating epileptic from non-epileptic myoclonus have been 
summarized by Hallet (Hallett, 1985). In general, epileptic myoclonus has an EEG correlate of 
spikes, multispikes and spike-wave or multispike-wave complexes. The EGM pattern for epileptic 
myoclonus usually consists of a short burst, <59 ms in duration, whereas non epileptic myoclonic 
events are associated with long bursts of 50-300 ms in duration (Hallett, 1985) 
 
 
Myoclonus and epilepsy 
 
Myoclonus and myoclonic seizures may associate to epilepsy in various combination. Positive 
myoclonus of cortical type associates to progressive encephalopathies such as Unverricht-Lundborg 
disease or Rasmussen pathology, and positive myoclonus of thalamo-cortical origin is usually 
associated to non-progressive generalized epilepsy and mainly involves idiopathic generalized 
epilepsies [i.e. Benign Myoclonic Epilepsy of Infancy (BMEI), Juvenile Myoclonic Epilepsy (JME), 
Severe Myoclonic Epilepsy of Infancy (SMEI), etc]. Myoclonus also associates to malformations 
and chromosomal aberrations such as Angelman syndrome. Therefore, myoclonus associates to 
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several kinds of epilepsies and its classification is sometimes very difficult. On the other hand, its 
classification is of high importance because counselling and treatment depend on accurate diagnosis 
and confusion between the different kinds of myoclonus may be devastating.  
Myoclonus can be classified in epileptic and non-epileptic myoclonus. Epileptic myoclonus is then 
divided in inherited and acquired type.  
Acquired myoclonic epilepsies are secondary to brain altering events which predispose the brain to 
manifest myoclonic epileptic symptoms. Such precipitating traumatic events may be represented by 
anoxia, head trauma, stroke, tumors, metabolic encephalopathies, degenerative central nervous 
system disease and/or viral infections (Leppik, 2003).  
Inherited myoclonic epilepsies are related to genetic alterations and can be divided in progressive 
and non progressive diseases. Non progressive myoclonic epilepsies are clinically stable and their 
symptoms do not progress in time. The most representative ones are: the Benign Myoclonic 
Epilepsy of Infancy (BMEI) and the Juvenile Myoclonic Epilepsy (JME). Both show generalized 
myoclonic epilepsy, tonic-clonic seizures and absence seizures. Other non progressive myoclonic 
disorders are: severe myoclonic epilepsy of infancy (SMEI) and myoclonic astatic epilepsy (MAE). 
Progressive myoclonic epilepsies (PME), on the other hand, show progression in symptoms with 
worsening of the clinical picture. Progressive myoclonic epilepsies are characterised by myoclonic 
seizures, tonic-clonic seizures, and progressive neurological deterioration. Myoclonus, in PME, is 
typically fragmentary and multifocal, and is often precipitated by posture, action, or external stimuli 
such as light, sound, or touch. It is particularly apparent in musculature of the face and distal 
extremities. Bilateral massive myoclonic jerks that tend to involve muscles of proximal limbs may 
also occur (Shahwan et al, 2005). The most representative PMEs are reported in tab 1. Among these, 
Unverrich-lundborg disease is the most common in the world population. Moreover, recent studies 
have been able to uncover the genetic alterations which underpin several PME (see table 1 for a 
schematic description and references).  
 
Table 1: genetic alterations of PME 
disease locus/chromosome protein references 
Unverricht-
Lundborg 
disease 
EPM1/21q22.3 Cystatin B (CSTB) Pennacchio et al. (1996) 
Lafora disease  EPM2/6q24 laforin Minassian et al. (1998), Ganesh et al. (2000) 
Neuronal 
ceroid 
lipofuscinosis 
(NCL) 
TTP1/11p15 
CLN3/16p12, 
CLN6/15q21, 
CLN5/13q22,              
trypeptidylpeptidase 
1 (NCL2) 
membrane protein 
CLN 
Sleat et al. (1997), Rawlings and Barret (1999), Vines 
and Warburton (1999)  
International Batten Disease Consortium (1995) ; Gao et 
al. (2002), Wheeler et al. (2002) ; Savukoski et al. (1998) 
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disease locus/chromosome protein references 
Myoclonic 
epilepsy with 
ragged red 
fibres 
(MERRF) 
MTTK/mtRNA tRNA for lysine Shoffner et al. (1990), Yoneda et al. (1990) 
Sialidoses NEU1/6p21 
NEU1/6p21  
e cr.20 
 α neuraminidase. 
(S type1) 
N-acetyl 
neuraminidase and 
β-galactosialidase, 
(S type 2) 
Bonten et al. (1996), Pshezhetsky et al. (1997) 
Dentatorubral-
pallidoluysian 
atrophy 
(DRPLA) 
DRPLA/12p13 atrophin 1 Shahwan et al. (2005), Leppik (2003) 
 
 
Clinical features of Unverricht-Lundborg disease 
 
Unverricht-Lundborg disease (ULD) 
The most common form of PME is the Unverricht–Lundborg disease (EPM1; OMIM #254800), an 
autosomal recessively inherited disorder. EPM1 was first described by Unverricht in 1891 and 
subsequently by Lundborg in 1903 (Unverricht, 1891; Lundborg, 1903). Initial epidemiology 
studies reported high incidence in defined world regions such as the Baltic peninsula and the 
mediterranean basin, giving it its first names of Baltic myoclonus (or Baltic myoclonic epilepsy) 
and Mediterranean myoclonus. In the last few decades, though, several have been the descriptions 
of this disease all over the world, making it more widely spread, and maybe underdiagnosed, then 
expected (Janssen, 1954; Shakir et al, 1992; Acharya et al, 1995; Vistorte et al, 1999; Mazarib et al, 
2001; Kalviainen et al 2008).  
Onset of this disorder, which occurs between 6 and 16 years of age, is characterized by stimulus-
sensitive myoclonic jerks in half of the patients, and generalized tonic clonic seizures in almost the 
other half, as first recognized symptoms. Myoclonus is usually precipitated by stimuli such as light, 
physical exertion, noise and stress. Either myoclonus and tonic-clonic seizures worsen in frequency 
and severity as the pathology progress, with their main evolution 5-10 and 3-7 years from disease 
onset respectively (Kalviainen et al 2008, Lehesjoki and Koskiniemi, 1999). During the progression 
of the disease, worsening of the myoclonus, which leads sometimes to status myoclonicus, makes 
one third of the patients severely incapacitated, like wheelchair bounded and unable to eat or drink 
by themselves (Kalviainen et al 2008). Neurological findings are initially absent or very mild, but, 
as the disease progresses, signs of cerebellar ataxia, incoordination, intentional tremor, and 
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dysarthria start to become evident (Kalviainen et al 2008; Lehesjoki and Koskiniemi, 1999; 
Shahwan et al, 2005). Mild intellectual performance impairment is also observed in patients with 
Unverricht-Lundborg disease which, however, maintain a relatively good mental alertness. In a few 
cases though, dementia may progress, leading to severe cognitive involvement (Shahwan et al, 
2005). Moreover, patients show emotional liability and depression (Kalviainen et al 2008).  
Debate on EEG characteristics is raging, questioning the initially reported slow background activity 
in EPM1 patients (Koskiniemi et al, 1974b). In fact, a retrospective evaluation of the EEG from 25 
ULD patients, reports no signs of slow background, or a very mild one (Ferlazzo et al, 2007). These 
discrepancies may be justified by the use, in the old studies, of therapies (such as phenytoin) that 
can worsen the clinical features of the pathology (Iivanainen and Himberg, 1982; Ferlazzo et al, 
2007). What seems to be true is that EEG abnormalities, such as spike-wave discharges, 
photosensitivity, and polyspike discharges during REM sleep (Tassinari et al., 1974), are more 
pronounced during the initial stages of the disease, usually associated to onset of myoclonus, tonic-
clonic seizures and their worsening, which in turn tend to diminish while, in years, the disease 
stabilizes. On average, in 15 years from disease onset a reduction of epileptic seizures and 
physiological sleep patterns are evident (Lehesjoki and Koskiniemi, 1999) reflecting a stabilization 
of the EEG (Kalviainen et al 2008).  
One MRI study reports very mild anatomical changes in patients in late stages of ULD, with loss of 
neuronal volume in pons, medulla and cerebellar hemispheres (Mascalchi et al, 2002). At disease 
onset MRI is usually normal.  
Outcome of the disease was very dramatic in the past, with patients dying before their thirties 
(Koskiniemi et al., 1974a, Lehesjoki and Koskiniemi, 1999). With the new therapeutic approaches 
life expectancy of EPM1 affected individuals has increased, spanning till their sixties or seventies 
(Kalviainen et al, 2008; Shahwan et al, 2005; Lehesjoki and Koskiniemi, 1999). Indeed, even tough 
pharmacological therapy for ULD is, unfortunately, only symptomatic, this leads to a much 
ameliorated condition. Valproic acid is the drug of choice for the management of myoclonus and 
can also reduce generalized seizure frequency (Shahwan et al, 2005; Kalviainen et al, 2008). 
Clonazepam and other benzodiazepines are used as add-on therapy for the treatment of myoclonic 
seizures or as intravenous emergency treatments when myoclonus is exacerbated in series or into 
status myoclonicus (Shahwan et al, 2005; Kalviainen et al, 2008). For emergency intervention 
valproate and levetiracetam prove the same efficacy (Kalviainen et al, 2008). Piracetam has been 
found useful only in myoclonus treatment and topiramate and zonisamide can be used as add-on 
therapies (Shahwan et al, 2005; Kalviainen et al, 2008). Phenytoin, and sodium channel blockers in 
general, must be avoided and GABAergic drugs (tiagabine and vigabatrin) as well as gabapentin 
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and pregabalin must not be used because they may aggravate myoclonus and myoclonic seizures 
(Shahwan et al, 2005; Kalviainen et al, 2008). Brivacetam, a SV2A ligand, which is under study 
and appear to provide a good control of seizures and myoclonus in epileptic experimental models, is 
being currently investigated as add-on therapy for ULD (Truong & Tai, 2005; von Rosenstiel, 2007). 
Management of Unverricht-Lundborg disease comprehend also psychosocial support, which is of 
key importance for a comprehensive rehabilitation of patients. Alleviating psychological liability 
and depression, usually associated to the disease, allows patients to be better accepted socially. A 
constant clinical follow-up is mandatory for EPM1 affected individuals (Kalviainen et al, 2008).  
Other therapeutic approaches are: vagus nerve stimulation, which reduces seizures and may 
significantly improve cerebellar function on neurological examination (Smith et al, 2000; 
Kalviainen et al, 2008), and apomorphine, due to the involvement of the dopaminergic system 
shown to underlie the pathogenesis of EPM1 (Mervaala et al, 1990; Korja et al, 2007). Indeed, 
apomorphine has been proven to be effective in a case of ULD (Mervaala et al, 1990). 
The molecular basis of Unverricht-Lundborg Disease has been identified using positional cloning 
techniques (Lehesjoki et al, 1991; Lehesjoki et al 1993; Pennacchio et al, 1996; Stone et al, 1996; 
Virtaneva et al, 1996). Alterations of the gene for Cystatin B are responsible for the phenotype. To 
date, 10 mutations have been reported (fig. 1) and the one related to a dodecamer expansion 
accounts for about 90% of affected individuals. The other gene alterations are point mutations 
responsible for miss-sense transduction, altered splicing, frame shifts and introduction of stop 
codons. An extensive description of molecular basis of the disease is reported below.       
Diagnosis for ULD has specific parameters to evaluate and occurrence of more than one of the 
following particular symptoms must be considered predictive of the disease: 
1. age of onset between 6 and 16 years 
2. evident or mild myoclonic jerks, especially if stimulus-precipitated 
3. experience of generalized tonic-clonic seizures 
4. mild neurological signs in motor function (i.e. clumsiness, mild dysmetria, mild ataxia) 
5. photosensitive induced EEG abnormalities (i.e. generalized spike-and-wave and 
polyspike-and-wave paroxysms)  
6. MRI uncovered brain anatomic changes such as cortical and central atrophy in old patients 
(MRI is normal in the beginning of the disease 
7. progression of initially reported symptoms, mostly myoclonus and neurological signs.  
Therefore, clinical diagnostic examination should include evaluation of walking, coordination, 
handwriting, school performance and emotional features. In addition, essential evaluation of 
myoclonus must be carried out in conditions of rest, action and in response to precipitating stimuli. 
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Confirmation of a diagnosis of ULD consists in genetic detection of the CSTB gene alteration 
(Kalviainen et al, 2008).    
 
 
Molecular basis of Unverricht-Lundborg disease 
 
Cystatin B (CSTB) 
EPM1 is associated with a defect in the cystatin B (CSTB) gene. The CSTB gene, positioned on 
chromosome 21 in the 21q22.3 locus, has been identified by positional cloning in the nineties 
(Lehesjoki et al, 1991; Lehesjoki et al 1993; Pennacchio et al, 1996; Stone et al, 1996; Virtaneva et 
al, 1996) it encodes Cystatin B, a cysteine protease inhibitor (Jarvinen and Rinne, 1982; Ritonja et 
al, 1985; Abrahamson et al, 2003).  CSTB is a member of the cystatin superfamily, which includes 
three distinct types: type-1 (also termed stefins), -2 and -3. Based on molecular properties and 
evolutionary relationship, CSTB is classified as a type-1 cystatin (Abrahamson et al, 2003). Firstly 
described as a cytoplasmic protein with apparent concentration at membranes of vesicular structures 
(Calkins et al, 1998), CSTB was then reported to be mainly nuclear in proliferating cells and present 
in both cytoplasm and nucleus in differentiated cells (Riccio et al, 2001).  
Principal substrates for CSTB are a group of proteins called cathepsins. Based on in in-vitro 
experiments, CSTB seems to mainly interact with cathepsins B, H, L and S (Jarvinen and Rinne, 
1982; Ritonja et al, 1985; Turk and Bode, 1991; Lenarcic et al, 1996; Saha and Usdin, 2001). In 
vivo, in lynphoblastoid cells from EPM1 patients, reduced expression of CSTB results in an 
increased B, L, and S cathepsin activity (Rinne et al, 2002) proving the fact that CSTB has a 
foudamental interaction with cathepsins. On the other hand, CSTB and cathepsins tissue 
distribution do not always overlap (Calkins et al, 1998) leading to think that CSTB may also act via 
other interactions. Indeed, Di Giaimo and coworkers reported a CSTB interaction with non-
cathepsin proteins in cerebellar cells. With GST-pull down and co-immunoprecipitation 
experiments Di Giaimo demonstrated CSTB involved in a multi-protein complex which function is 
still unknown (Di Giaimo et al, 2002).   
Structurally, CSTB is a low weight protein of about 100 amino-acid in length with no disulphide 
bonds; its secondary structure consists of a five-stranded beta sheet wrapped around a five-turn 
alpha helix (the human one contains an additional C-terminal strand that runs along the convex side 
of the beta sheet) (Bode et al, 1988; Stubbs  et al, 1990). Three have been demonstrated to be the 
sites of major interaction for cathepsins on CSTB: 1) a Glycine at N-terminal of the protein, 2) a 
highly conserved amino acid sequence, QVVAG, in the middle of the peptide and 3) LP at the C-
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terminus (Stubbs et al, 1990). The extended C-terminal region in human CSTB introduces an 
additional hydrophobic interacting site (Joensuu et al, 2007). 
The main function of CSTB, as of other cystatins of the family, is to ensure protection of cells 
against the proteolytic activity of lysosomal peptidases (cathepsins in the CSTB case) that are 
released occasionally during normal cell death or activated by proliferating cancer cells. Indeed, the 
main function of cathepsins is the nonselective degradation of intracellular proteins to peptides and 
amino acids, but they also participate in antigen processing (Turk et al., 2000; Rinne et al., 2002). 
Cathepsins have been also involved in apoptosis and caspase-independent cell-death (such as 
autophagy, paraptosis and slow cell death) leading to the idea that CSTB can indirectly regulate, in 
physiological conditions, cathepsins action on these two phenomena (Broker et al, 2005; 
Chwieralski et al, 2006).    
 
Molecular alterations of CSTB leading to the Unverricht-Lundborg phenotype. 
To date, 10 genetic alterations have been related to ULD phenotype (fig. 1) 
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5’UTR EX1 EX3EX2 3’UTRIVS1 IVS2
CCCCGCCCCGCG
ATG STOP
1
2
3
4 5
6 7
8 9 10
p.L73fsX3
p.Q71P
p.R68X
Aberrant splicing?
p.delV23_K56 
p.V57EfsX28
Aberrant splicing?
p.G50E
p.delV23_K56
p.G4R
Reduced CSTB expression
Consequence on protein
c.218_219delTC
c.212A>C
c.202C>T
c.169–2A>G
c.168 + 1_18del
c.168>A
c.149G>A
c.67–1G>C
c.10G>C
Dodecamer repeat 
expansion
Mutation type referencesPosition of mutation/type
Lafrèniere et al. (1997), Lalioti et al. (1997b), 
Virtaneva et al. (1997)
5’ UTR/expansion
Lalioti et al. (1997a)Exon 1/missense
Joensuu et al. (2007)Intron 2/deletion
Pennacchio et al. (1996); Lafrèniere et al. (1997), 
de Haan et al. (2004)
Intron 2/splice site
Pennacchio et al. (1996), Lafrèniere et al. (1997), 
de Haan et al. (2004)
Exon 3/nonsense
de Haan et al. (2004)Exon 3/missense
Bespalova et al. (1997a), Lafrèniere et al. (1997),
Lalioti et al. (1997a)
Exon 3/deletion
Kagitani-Shimono et al. (2002)Exon 2/splice site
Joensuu et al. (2007)Exon 2/missense
Pennacchio et al. (1996), Bespalova et al. (1997b), 
Lafrèniere et al. (1997), Lalioti et al. (1997a)
Intron 1/splice site
1
2
3
4
5
6
7
8
9
10
Dodecamer repeat expansion Missense mutation Delet ion  mutation Splicing site  mutation nonsense  mutation
 
fig. 1: Genetic modifications associated to ULD phenotype. (adapted from Joensuu et al 2008). 
 
Among these, the 12-nucleotide repeat unstable expansion accounts for about 90% of EPM1 
affected individuals (Pennacchio et al., 1996; Bespalova et al., 1997; Lafreniere et al., 1997; Lalioti 
et al., 1997a, 1997b; Virtaneva et al., 1997; Kagitani-Shimono et al., 2002; Joensuu et al., 2007). 
The 5’-CCCCGCCCCGCG-3’ dodecamer is found at 175 bp from the promoter region of the 
normal CSTB gene in 2-3 copies and results in a functional expressing gene. The expansion of at 
least 30 copies of this dodecamer alters the CSTB gene reducing its mRNA expression to less than 
10% (Joensuu et al, 2007) and, consequently, to a very low expression of its own protein (Rinne et 
al, 2002). The worst case reported has 125 repetitions of the dodecamer in its promoter region 
(Virtaneva et al, 1997). Human pre-mutation, found to date only in the form of 12 to 17 dodecamer 
copies (Lalioti et al, 1997b; Alakurtti et al, 2000), caused a reduced mRNA expression with no 
evident symptoms compatible with EPM1. To date, no other kind of pre-mutation has been found in 
the human population. Correlations between the length of dodecamer expansion and phenotype, 
mainly age of onset and severity, have never been found. The lowest expression level of CSTB 
protein compatible with a normal phenotype is yet to be determined (Joensuu et al, 2008).  
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The reduction of gene expression due to the dodecamer expansion can be explained in different 
ways: 
o dodecamer repetition introduces more space between promoter elements, leading to the 
impossibility for the transcription factor complex to properly interact with the promoter 
region (Lalioti et al, 1999) 
o dodecamer repetition allow DNA to form tetraplex secondary structures which, again, result 
in disrupt spacing of promoter elements and in turn to reduced transcription of the gene. 
Even mRNA could be affected by reduced transduction decreasing the quantity of protein 
available. (Pataskar et al, 2001; Saha and Usdin, 2001) 
o iper-methylation may be another mechanism for the reduced expression of the CSTB gene 
altered by dodecamer repetition, but experimental data do not support this evidence (Lalioti 
et al, 1997b).  
The nine remaining CSTB mutations underlying EPM1 affect splice sites (c.67–1G>C, c.168G>A, 
c.168 + 1 18del, c.169–2A>G), result in amino acid changes (c.10G>C, p.G4R; c.149G>A, p.G50E; 
c.212A>C, p.Q71P) or predict truncated proteins (c.202C>T, c.218 219delTC) by producing a 
premature stop codon (p.R68X) or a frameshift (p.L73fsX3) (fig 1). These mutations usually appear 
in compound heterozygous form with the dodecamer expansion.  
Only p.G4R has been reported to be capable to induce the EPM1 phenotype alone (Lalioti et al, 
1997a). This mutation results in substitution of highly conserved Glycine amino acids in position 4 
of the protein, with disruption of important interaction sites of CSTB with cathepsins. This latter 
mechanism seems also to be the base for the other miss-sense mutations.  
Because of the high prevalence of the dodecamer expansion mutation in individuals affected by 
ULD, we can conclude that a general loss of function for the CSTB protein, mainly due to its 
decreased expression, seems to be the primary pathological mechanism in the majority of EPM1 
patients.  
Another, still not fully identified, mutation has been associated to an inbred Arab family by 
Berkovic and collaborators which found, through homozygosity mapping in a genomewide scan, 
another underlying locus for EPM1 (called EPM1B) linked to a 15-megabase region on 
chromosome 12 (Berkovic et al., 2005). The corresponding mutated gene remains to be identified. 
This new finding complicates the genetic picture for Unverricht-Lundborg disease, implying that 
other, still unknown, genes may be involved in establishing the EPM1 phenotype.  
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CSTB Knock-out mice: an animal model of Unverricht-Lundborg disease 
 
A mouse model for the human disease has been developed by targeted disruption of the CSTB gene 
(Pennacchio et al., 1998). Mice have been created on the base of two genetic background: isogenic 
129Svj and mixed background of C57Bl6/129Svj. Several studies support the notion that, in general, 
CSTB knock-out (KO) mice are a good model of EPM1. Indeed, CSTB knock-out mice display a 
behavioural phenotype that replicates main symptoms reported in human patients, including 
progressive ataxia and myoclonic jerks, although convulsive seizures appear to be rare (Pennacchio 
et al., 1998). In mice, myoclonus is not stimulus sensitive and action activated as it is in humans, 
but develops already at 1 month of age during sleep and only in mice with an isogenic 129Svj 
background (Pennacchio et al, 1998). Moreover, no tonic–clonic seizures, photosensitivity, or 
spike-wave complexes in EEG have been observed in KO mice (Joensuu et al, 2008). Progressive 
ataxia starts in mice around 6 months of age as shown by still and rotating rotarod tests (Pennacchio 
et al, 1998). Ataxia is independent from genetic background. Analysis of the CSTB-deficient brain, 
in keeping with human studies (Haltia et al., 1969, Koskiniemi et al., 1974a, Eldridge et al., 1983, 
Mascalchi et al., 2002, Lehesjoki, 2003), reveals the presence of apoptosis, mainly involving 
cerebellar granule cells (Pennacchio et al., 1998), and cerebellar atrophy (Shannon et al., 2002). It 
has also been reported that neuronal apoptosis associated with gliosis involve other brain structures, 
including the cortical and subcortical grey matter (Shannon et al., 2002). These findings are in line 
with the notion that CSTB has a role in preventing cell damage and, thus, EPM1 may be classified 
as a primary neurodegenerative disorder.  
Other features of CSTB KO mice, even though not in line with human phenotype, are development 
of progressive corneal lesions that start around three months of age (Pennacchio et al, 1998) and a 
significant reduction of body and brain weight (Shannon et al, 2002). 
Since their creation, CSTB KO mice helped to shed light on the molecular and structural alterations 
associated to CSTB deficiency. 
1. Lieuallen and collaborators demonstrated, in micro-array experiments, that Cystatin B 
deficiency leads to over-expression of cathepsins S, C1q B-chain of complement, beta2 
microglobulin, glial fibrillary acid protein, apoliprotein D, fibronectin one and 
metallothionein II in the brain of CSTB KO mice, which are expected to be involved in 
increased proteolysis, apoptosis and glial activation (Liueallen et al, 2001).  
2. In a study involving double mutant CSTB KO/Bid KO mice, Houseweart and collaborator 
found that cathepsins are still able to promote apoptosis even in the absence of Bid, 
indicating that these proteases mediate apoptosis via a different pathway, or that some other 
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molecule can functionally substitute for Bid in this system (Houseweart et al, 2003b).  
3. Again, Houseweart and colleagues demonstrated that removal of cathepsins L or S from 
cystatin B-deficient mice did not ameliorate any aspect of the EPM1 phenotype, but 
removal of cathepsin B resulted in a 36–89% reduction in the amount of cerebellar granule 
cell apoptosis depending on the mouse age. These findings establish cathepsin B as a 
contributor to the apoptotic phenotype of cystatin B-deficient mice and humans with EPM1. 
They also suggest that the identification of cathepsin B substrates may further reveal the 
molecular basis for EPM1 (Houseweart et al, 2003a). 
4. Arbatova and colleagues demonstrated that the tryptophan metabolism along 5-HT and 
KYN pathways is disrupted in EPM1 (Arbatova et al, 2005).  
5. Kopitar-Jerala et al. found that sensitization to apoptosis induced by STS in thymocytes of 
CSTB-deficient and wild-type mice is not dependent on cathepsin inhibition by stefin B 
(Kopitar-Jerala et al, 2005). 
6. Kopitar-Jerala and Turk observed increased cleavage of MARCKS in brain and 
macrophages of CSTB-deficient mice compared to wild-type mice. They also showed that  
processing of cathepsin B was unaltered in the brain of CSTB-deficient mice, leading to the 
conclusion that increased cleavage of MARCKS could be attributed to the lack of inhibitor 
(Kopitar-Jerala and Turk, 2007). 
7. Kaasik et al, showed a partial decrease in cystatin B expression in heterozygous mice for 
CSTB, which in turn leads to development of a mild EPM1 phenotype (Kaasik et al, 2007). 
8. Cipollini  et al showed that, in vivo, in the CSTB KO model, cystatin B has a highly 
resistant, polymeric structure which is sensitive to the redox environment and when over-
expressed generates aggregates (Cipollini et al, 2008).  
9. O. H. Manninen and collaborators detected, by the means of MRI, a significant decrease in 
volume of the whole brain, hippocampus and striatum in the CSTB KO mice. Moreover, 
the MRS revealed significant differences in metabolic profiles between the two groups, 
which showed significant decreases in glutamate, N-acetyl aspartate, taurine, and other 
metabolites (Manninen et al, 2008).  
 
In conclusion, CSTB KO mice mimic fairly well the human disease and represent a very good tool 
to study the pathophysiology of Unverricht-Lundborg disease and to uncover the still hidden 
functions of Cystatin B in the brain and in other tissues. Extensive investigation on this animal 
model may shed light on the mechanisms underpinning EPM1 leading to a possible, more targeted, 
therapy for ULD affected individuals.  
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AIM OF THIS STUDY 
 
This study has been designed to begin exploring the mechanism of EPM1 onset and progression. 
Our working hypothesis stems from the observation that treatments capable of counteracting 
seizures are also capable of lessening the rate of disease progression. This suggests that seizure-
linked excitotoxic events (see, for a review, Sutula et al., 2003) might play a role in determining the 
progression of the degenerative processes sustaining the severity of the disease. Thus, we 
hypothesized that the onset of the disease may be related to a latent hyperexcitability of the EPM1 
brain, and that the progression may depend on higher susceptibility to seizure-induced damage. 
To challenge this hypothesis, we performed a series of experiments in the CSTB-deficient mouse 
model of EPM1. First, by means of electrophysiological recordings, we investigated the presence of 
changes in excitability and in susceptibility to seizures in the hippocampus of CSTB-deficient mice 
in vitro. Second, we explored the susceptibility of CSTB-deficient mice to kainate induced 
generalized seizures and to seizure-induced damage in vivo, by analysing markers of degeneration. 
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Chapter III 
 
Fragile X 
Dendritic targeting of Fmr1 and FMRP in a model of status epilepticus. 
 
 
(based on submitted paper Ferrari et al.) 
(work have been conducted in collaboration with the University of Rome, Torvergata, with Prof. Claudia Bagni and collaborators)
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INTRODUCTION 
 
 
Fragile X  
 
Fragile X syndrome (FXS) is the most common inherited cause of mental retardation. Being an X-
linked pathology, prevalence results worse in male than females with values of 1 out of 4000 for 
males and 1 out of 8000 for females (Crawford et al, 2001). FXS is an X-linked dominant disorder 
which inheritance transmission follows what is called Sherman Paradox. Genetic penetrance for the 
disease increases in succeeding generations of the pedigree (O’Donnell and Warren, 2002), with 
non penetrant male carrier of the Fragile X gene defect which transmits its modified allele to a non 
penetrant daughter which, in turn, may give birth to full mutant off-springs (Sherman et al, 1985; Fu 
et al, 1991; Bassell and Warren, 2008).  
This particular inheritance is due to the genetic characteristics of the defect associated to the 
pathology: a trinucleotide (CGG) expansion in the 5’untranslated (UTR) region of the fmr1 gene 
positioned on the X chromosome.   
Fmr1 has been identified as the main cause for FXS by Verkerk and collaborators (Verkerk et al, 
1991) using the positional cloning technique; this has been the first example of a trinucleotide 
repeat mutation. The principal mutation on this gene is the reported expansion of the CGG triplet in 
its 5’UTR. Normal alleles contain less then 40 repetitions for CGG trinucleotide, with an average 
30 trinucleotides expansion (Snow et al, 1993). The full mutation, instead, is more then 200 
trinucleotide repetitions (Snow et al, 1993; Fu et al, 1991). Average repetitions in full mutation 
usually span in the order of 800 triplets. Individuals with that many triplets show the full phenotype 
of Fragile X. In between there are other two situations: one called intermediate allele with 41-54 
repetitions, which does not associate with gene instability, and phenotypical features, and 
premutation allele, which spans from 55 to 200 repetitions (Garber et al, 2008). Premutations are 
meiotically unstable (Snow et al, 1993; Fu et al, 1991) and are not clinically phenotype free. Indeed, 
the premutation allele associates with two different adult syndromes: FXTAS, Fragile X Tremor 
and Ataxia Syndrome, and POF, Premature Ovarian Failure. FXTAS appears in a subgroup of men 
presenting premutation which develop neurological symptoms beyond age 50: intentional tremors, 
balance problems, frequent falls, neuropathy, autonomic dysfunction, cognitive decline and 
progressive dementia (Jacquemont et al, 2004; Willemsen et al, 2005). FXTAS has a very low 
prevalence in females. POF occurs in about 20% of women carriers for the premutation and is 
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represented by premature cessation of menses before age 40 (Allingham-Hawkins et al, 1999). Both 
clinical manifestations seem paradoxally related to an over expression of fmr1 mRNA, which 
occurs only in premutation carriers (Cornish et al, 2008).    
Since when repeat expansion has been discovered and thought to be the main cause for FXS (98-
99% of FXS individuals has this kind of mutation), other conventional mutations, such as non-sense 
and missense mutations, for fmr1 went underestimated (Bassell and Warren, 2008), even tough, 1% 
of FXS displaying patients have recognised missense mutations (Sherman et al, 2005; Feng et a. 
1997a).  
The full mutation associates with hypermethylation, which is responsible for silencing fmr1 gene 
expression (Sutcliffe et al, 1992; Coffee et al, 1999). The phenotype for Fragile X is therefore due 
to absence of FMRP, the protein product of the fmr1 gene.  
FMRP is a protein of about 71 KDa, depending on its different isoforms deriving from alternative 
splicing of the fmr1 gene (Bassell and Warren, 2008). FMRP, an mRNA binding protein (Ashley et 
al, 1993), is widely expressed in several tissues included the brain, where is thought to play an 
important role in regulating mRNA expression (Bassell and Warren, 2008). Structurally, it is a 
protein expressing both signals for nuclear localization and for nuclear export, and it seems to 
shuttles between nucleus and cytoplasm of the cells (Eberhart et al, 1996; Sittler et al, 1996). The 
best characterized motifs on FMRP are two hnRNP-K-homology (KH) domains and an Arginine-
Glycine-Glycine (RGG) box. In in-vitro experiments the, RGG box recognize a stem-G-quartet loop 
structure in RNA and most of the RNAs that have been associated to FMRP (Brown et al, 2001; 
Darnell et al, 2001) seem to contain this structure. Several studies confirm this interaction and 
enlarge this concept to a more general interaction of the RGG box to G-rich regions, including G-
quartet regions (Menon et al, 2008; Menon and Mihailescu, 2007; Schaeffer et al, 2001; Lu et al, 
2004; Zalfa et al, 2003; Zhang et al, 2001; Zalfa et al, 2007; Todd et al, 2003; Darnell et al, 2001; 
Westmark and Malter, 2007). The putative role of KH-domains is to bind FMRP to actively 
translating polyribosomes (Feng et al, 1997b; Khandjian et al, 2004; Stefani et al, 2004). Their 
possible interactions with mRNAs are still unclear: current hypothesis include the formation of the 
so called “kissing complex”, represented by more then one mRNA that, combined, create a KH 
recognized structure (Darnell et al, 2005) or by mRNA complexed with microRNAs that allow 
indirect interaction between KH FMRP domains and mRNAs (Jin et al, 2004). Another possible 
interaction is the controversial binding of FMRP to mRNA through BC1 RNA (Zalfa et al, 2003; 
Iacoangeli et al, 2008a; Bagni, 2008; Iacoangeli et al, 2008b). 
Due to the above described interactions, FMRP is thought to regulate local protein synthesis (Antar 
and Bassell, 2003; Bagni and Greenough, 2005; Grossman et al, 2006) and several works support 
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the hypothesis that FMRP binds and regulates expression of dendritic mRNAs (Antar et al, 2005; 
Kindler et al, 2004; Miyashiro et al, 2003; Zalfa et al, 2003; Bramham and Wells, 2007). FMRP has 
not been demonstrated to be important for steady-state maintenance or constitutive localization of 
mRNAs at the dendrites (Steward et al, 1998; Muddashetty et al, 2007; Miyashiro 2003) and its role 
in mRNA stabilization is debated (Zalfa et al, 2007; Muddashetty et al, 2007). More convincing 
evidence suggests that FMRP may be implicated in shuttling a subset of dendritic mRNAs, 
accordingly to a model  whereby the dynamic association of FMRP with translationally repressed, 
microtubule-associated mRNP complexes and polyribosomes might be a mechanism linking mRNA 
transport in dendrites with translational regulation at synapses (Wang et al., 2008). 
Regulation of mRNAs expression by FMRP is mainly repressive, leading to an excessive protein 
synthesis when FMRP is absent, as happens in FXS. In FXS excess protein expression is found 
even under steady-state conditions, leading to reduced plasticity response (i.e. increased protein 
synthesis) to synaptic activation. The prevalent view in fragile X syndrome is that the synaptic 
dysfunction and cognitive impairment are the result of excess protein synthesis at the synapse 
(Ronesi and Huber, 2008) and, while the excess translation is likely to be a major cause, it may be 
of equal concern that there is a loss of stimulus-induced translation. The inability of synapses in the 
FXS brain to control where and when translation precisely occurs and the inability to augment 
translation in response to synaptic activity are likely to have consequences on long-term plasticity, 
which influences learning and memory. Indeed, a loss of protein synthesis-dependent plasticity has 
been observed, at least with regard to Gp1 mGluR LTD (Hou et al., 2006; Huber et al., 2002) which 
introduce to the so called mGluR theory of fragile X syndrome. This theory states that FMRP 
normally acts as a negative regulator of translation downstream of Gp1 mGluRs and, in the absence 
of FMRP, there is an increase in protein synthesis that leads to excessive AMPAR internalization 
and exaggerated LTD (Bear et al., 2004). In addition, the mGluR theory suggests that many of the 
synaptic phenotypes in FXS may be directly attributed to exaggerated mGluR signaling, and 
therefore mGluR antagonists could be a useful therapy for FXS. There is solid evidence to support 
this theory (McBride et al, 2005; Tucker et al, 2006; Yan et al, 2005).  
A model for FMRP functions and dynamic activation/repression in neurons is reported in figure 1 . 
 60
 
(from Bassel and Warren, 2008).  
Figure 1: The Stimulated Travels and Function of FMRP throughout the Neuron.  
FMRP is in a complex with several translationally arrested mRNAs at the synapse. Following mGluR stimulation, FMRP-target mRNAs are rapidly 
derepressed, allowing for local translation. A second phase of FMRP-dependent plasticity is shown that involves the subsequent transport of new 
mRNAs from the cell body into dendrites. The model shown here illustrates translational repression at the level of elongation, as suggested by Ceman 
et al. (2003). The translational activation and repression of mRNA is regulated by a PP2A/S6K1 signaling module (Narayanan et al., 2007; Narayanan 
et al., 2008). (1) Upon mGluR1/5 activation, PP2A is rapidly activated and dephosphorylates FMRP, thereby allowing for (2) local translation of 
proteins that affect AMPAR trafficking, i.e., PSD-95, Arc, Map1b, and App (Westmark and Malter, 2007; Todd et al., 2003; Muddashetty et al., 2007; 
Hou et al., 2006; Davidkova and Carroll, 2007; Waung et al., 2008; Park et al., 2008). Following mGluR activation, FMRP is rephosphorylated by 
S6K1 with slower kinetics, leading to translational repression. (3) FMRP can also be ubiquitinated following mGluR stimulation, and its proteosome-
dependent degradation is necessary for mGluR-LTD (Hou et al., 2006). The local degradation of FMRP may contribute to local protein synthesis 
underlying mGluR-LTD. A mechanism of local FMRP degradation may be balanced by its synthesis. FMRP is synthesized in synaptoneurosomes 
upon mGluR activation (Weiler et al., 1997), which may provide a feedback mechanism to restore translational repression. Upon mGluR stimulation, 
(4) there may be a retrograde signal that leads to the transport of new FMRP-associated mRNAs from the soma. The active bidirectional transport of 
FMRP granules in dendrites has recently been described (Dictenberg et al., 2008). This model speculates that FMRP itself may traffic from the 
synapse to the cell body and/or nucleus, where it may complex with new target mRNAs, and return to the activated synapse. (5) In that FMRP can 
shuttle into the nucleus (Eberhart et al., 1996), it will be interesting to assess whether nucleocytoplasmic trafficking is regulated by mGluR signaling. 
(6) FMRP has recently been shown to be necessary for the transport of several mRNAs into dendrites, whereas neurons cultured from Fmr1 KO mice 
show impaired mRNA transport dynamics (Dictenberg et al., 2008). This model speculates that the trafficking population of FMRP is phosphorylated; 
however, future work is needed to assess whether FMRP phosphorylation may influence mRNA trafficking. 
 
 
FXS affects the individual from birth, even tough it becomes evident only when retardation in the 
developmental milestones (such as motor and/or language delays) becomes evident. Individuals 
affected by FXS display very subtle physical characteristics all involving connective tissue 
dysplasia that brings to long and narrow face, prominent ears, joint hypermobility and flat feet 
(Hagerman et al, 1984). Macro-orchidism is also present and become apparent just prior puberty 
(Lachiewicz and Dawson, 1994).  
Behavioural aspects of this disease comprehend autistic-like features including hand flapping, hand 
biting, gaze avoidance, tactile defensiveness and hyperarousal to sensory stimuli (Hagerman et al, 
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1986; Brown et al, 1986). All these features are expressed in varying degrees in children with FXS. 
Other features may be anxiety, mood disorders, hyperactivity, impulsivity and aggressive behaviour. 
Females with FXS display an higher emotional instability being more prone to social anxiety, 
shyness, social avoidance, withdrawal, language deficits, mood lability, and depression (Freund et 
al, 1993). Average IQ for full mutation affected patients may vary depending on degree of 
methylation of the triplet expansion. Fully methylated trinucleotide expansions lead to a very low 
IQ score of about 40 (Merenstein et al, 1996) but, when CGG repeats are not fully methylated, the 
IQ score is in the borderline or low normal range. Cognitive deficiency for FXS patients consists of 
working and short-term memory problems, impairment of executive function and mathematic and 
visuospatial abilities (Kemper et al, 1988). Females are much less impaired in cognitive function 
but, as already stated before, show a higher risk for emotional problems (Freund et al, 1993).  
Neuroanatomical analysis of the FXS brain shows no gross abnormalities, but neurons have 
immature and dense dendritic spines: this is a neuroanatomical key feature in FXS (Irwing et al, 
2001). It is believed that these differences represent a defect in dendritic spine development and 
maturation.  
Finally, about 20% of FXS affected individuals present with seizures, correlating FXS to epileptic 
phenomena.  
Diagnosis for FXS is based on clinical observation of developmental delay which eventually leads 
to a FXS molecular testing. Genetic testing for the CGG expansion consists of PCR analysis, with 
primers designed for the flanking regions of the expansion mutation, and southern Blot, that 
measures the entity of the expansion. Sequencing of the fmr1 gene should be considered in the 1% 
of patients that display the clinical features of FXS and no expansion mutation is revealed by PCR 
and Southern Blot (Garber et al, 2008). Prenatal diagnosis has been performed and proved to be 
highly reliable (Brown et al, 1993). 
Treatment for FXS is mainly symptomatic. Psychopharmacological therapies are usually combined 
with supportive strategies including speech therapy, sensory integration occupational therapy, 
individualized educational plans and tailored behavioural interventions to maximize functioning 
(Garber et al, 2008). General pharmacological approach consists of stimulants for symptoms of 
hyperactivity, impulsivity and distractability (Berry-Kravis and Potanos, 2004); of alfa-2-
adrenergic agonists, which may control response to sensory input and provide good containment of  
hyperarousal behaviour (Berry-Kravis and Potanos, 2004); of selective serotonin reuptake 
inhibitors, quite often used to treat mood disorder, anxiety and obsessive-compulsive behaviours; of 
atypical antipsychotics, (drug of choice: aripiprazole), used to prevent self injury, aggressive 
behaviour and autism. Based on the mGluRs theory, antagonists for this system may become a good 
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tool to treat several aspect of FXS (Bear et al, 2004); indeed, mGluR5 antagonists are under 
investigation and preclinical reports showed good results (Slassi et al, 2005; Berry-Kravis et al, 
2006). Of course, the surrounding environment is essential in the outcome of Fragile X affected 
individuals and environmental variables may influence the development of adaptative behaviour, 
cognitive abilities and behavioural symptoms. 
Due to the very complex molecular picture drawn for the function of FMRP and the highly 
differentiated clinical outcome associated to FXS, it is of high importance to better understand how 
a single gene silencing mutation may lead to all the features described, in order to better address the 
therapeutic efforts designed to ameliorate the condition of Fragile X patients.  
 
 
Fragile X and Epilepsy 
 
Epilepsy associates to the Fragile X phenotype in almost 20-25% of the cases (Berry-Kravis, 2002; 
Incorpora et al, 2002; Sabaratnam et al, 2001; Musumeci et al, 1999). Although high variability is 
associated in human studies for the onset and recurrence of seizures, FragileX-related-seizures 
generally appear around early childhood and usually disappear in a period that spans from 
adolescence through early adulthood (Kluger et al, 1996; Musumeci et al, 1999; Sabaratnam et al, 
2001). Semiology of Fragile X–linked-epilepsy shows a variable phenotype and, although 
generalized seizures have been reported as the prominent ones (Wisniewski et al, 1991), some other 
authors report that complex partial seizures also appear with high frequency (Musumeci et al, 1999; 
Sabaratnam et al, 2001). According to the literature (Musumeci et al, 1991), types of seizures in 
Fra-X present similarities with some epilepsy syndromes such as benign childhood epilepsy with 
centrotemporal spikes (BCECTS (*)) (Aicardi, 1986), childhood epilepsy with occipital paroxysms 
(Gastaut, 1982), partial motor seizures with adversion in patients with extreme somatosensory 
evoked potential (DeMarco and Tassinari, 1981; Plasmati et al, 1992), Landau– Kleffner syndrome 
(Landau and Kleffner, 1957), partial frontal epilepsy with favourable evolution (Beaumanoir and 
Nahory, 1983), and status epilepticus during sleep (Tassinari et al, 1982). Main correlation reported 
in literature is with BCECTS, with which FXS-linked epilepsy share, in most of the cases, benign 
outcome and EEG pattern (Incorpora et al, 2002; Berry-Kravis et al, 2002; Sabaratnam et al, 2001; 
Musumeci et al, 1999; Kluger et al, 1996). Some works have also been directed to find a genetic 
correlation between BCECTS and FXS but no molecular association has been demonstrated to date 
(Kluger et al, 1996; Rees et al, 1993).  
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(*)Benign Childhood Epilepsy with Centrotemporal Spikes (BCECTS) 
Benign epilepsy of childhood with centrotemporal spikes (BCECTS) is the most common partial epilepsy syndrome in the pediatric age group, with 
an onset between age 3 and 13 years. The typical presentation is a partial seizure with parasthesias and tonic or clonic activity of the lower face 
associated with drooling and dysarthria. Seizures commonly occur at night and may become secondarily generalized. They are usually infrequent and 
may not require antiepileptic drugs but, if treated, they tend to be easily controlled. Children with BECT are neurologically and cognitively normal. 
The EEG shows characteristic high-voltage sharp waves in the centrotemporal regions, which are activated with drowsiness and sleep. In this typical 
form, BCECTS is easily recognized. 
However, atypical cases are common and the definition of BCECTS can become blurred. Although further investigations are not required in cases 
with typical clinical and EEG findings and normal neurologic examinations, neuroimaging studies may be required in atypical cases to rule out other 
pathology. The long-term medical and psychosocial prognosis of BCECTS is excellent, with essentially all children entering long-term remission by 
mid-adolescence (Wirrel, 1998). 
 
Most of the cases of epilepsy associated to FXS have, as in the BCECTS, a benign course 
responding well to anticonvulsant therapy, mainly carbamazepine, and with a high incidence of 
total remission of the symptoms within childhood or adolescence (Sabaratnam et al, 2001). Even 
though this is the general outcome of the epileptic disease linked to FXS, some patients still 
experience seizures during adulthood and sometimes are unable to control the pathology by AEDs 
therapy (Musumeci et al, 1988; Incorpora et al, 2002).  
EEG analysis of FXS patient, aside finding analogies with BCECTS, reveales a particular EEG 
pattern that associates to about 50% of Fragile X affected individuals, even in those that do not 
show seizures. Common EEG features are slow background and abnormal intermittent rhythmic 
theta or delta activity (Sarabatnam et al, 2001; Wisniewski et al, 1991; Musumeci et al, 1991; 
Vieregge and Froster-Iskenius, 1989). EEG activity, either in epileptic patients or in patients not 
showing any seizure, has been reported as age-dependent because of its relation to a particular 
period of time that spans from childhood, when the EEG pattern usually appears, and late 
adolescence-early adulthood, when the EEG pattern slowly disappear (Musumeci et al, 1999; 
Kluger et al, 1996). EEG activity is usually stronger and dramatically activated by sleep (Musumeci 
et al, 1999; Kluger et al, 1996). The significance for this EEG alterations in FXS patients is not 
clear and different hypothesis have been proposed. Vieregge and Froster-Iskenius suggested the 
dendritic spine abnormalities observed in fragile X syndrome as the cause of excessive neuronal 
excitation and spiking (Vieregge and Froster-Iskenius, 1989). This would also be in line with the 
idea that impairment in brain maturation is at the base of EEG abnormalities in FXS and in 
BCECTS. Another possible cause could be a deficit of GABA neurotransmission; Binstock has 
proposed that the absence of the FMRP leads to a dysfunction in the GABAergic system (Binstock, 
1995). Indeed, recent studies demonstrate that GABAergic inhibition is impaired in different ways, 
at cellular (Selby et al, 2007), physiological (Curia et al, 2008b; Centonze et al, 2008) and 
molecular level (El Idrissi et al, 2005; Curia et al, 2008; D’Hulst et al, 2006). Therefore, decrease of 
interneurons number, altered GABAergic transmission and/or altered GABA-A subunit expression 
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may be the cause for the epileptic seizures and/or the EEG abnormalities associated to FXS. Finally, 
Kluger, who performed EEGs in children with fragile X and genetic analysis on children with 
BCECTS, has suggested that the final common pathway of impairment in the two conditions is the 
FMR-1 gene (Kluger et al, 1996). The latter hypothesis still awaits experimental confirmation. 
Brain excitability and susceptibility to seizures has been shown also in mice deficient for Fmr1, the 
genetic model reproducing FXS in mice (Bakker et al, 1994; Kooy et al, 1996). Even if the mouse 
model for FXS does not display spontaneous seizures, it is susceptible to audiogenic induced 
seizures (Musumeci et al,  2000; Chen and Toth, 2001; Kooy, 2003). Although seizures age 
dependency is still on debate, a trend has been reported with older mice more prone to acustic 
seizures (Chen and Toth, 2001; Kooy, 2003). Chemically induced seizures, by the means of kainic 
acid, bicuculline and pentylentatrazole injection, do not show difference between null Fmr1 mice 
and their controls, suggesting that Fmr1 KO mice have specific susceptibility to audiogenic stimuli 
(Todd and Mack,  2000; Chen and Toth, 2001). Possible explanation for this specific susceptibility 
in Fmr1 Knock out mice may be related to an increased cortical excitability or connected to a 
deficiency in long-term plasticity (Kooy, 2003). Indeed, as proposed by Chen and Toth, a 
developmental impairment of the auditory system may occur in fragile X mice (Chen and Toth, 
2001).  
In conclusion, there is still a huge amount of work to do to uncover the implication of Fmr1 
mutation in epilepsy. Human studies are very important to deeply describe the follow up of the 
pathology and to widely report the subtle differences among the patients. Preclinical investigation, 
on the other side, may shed light on the intrinsic mechanisms that may apply to the still unclear 
functions of Fmr1-FMRP. Therefore, it is of vital importance to deepen our knowledge on every 
aspect of the manifestations of FXS, in order to better target the efforts in dealing with the 
pathology and making amelioration possible.       
              
 
Pilocarpine 
 
The pilocarpine model is a model of Temporal Lobe Epilepsy (for en extensive review see Curia et 
al, 2008a). It is an isomorphic model capable to reproduce the main features of the epileptic 
disorder. Implications of the cholinergic system in epileptic phenomena have been demonstrated 
since the beginning of last century, when it resulted clear that cholinergic agonists induce seizures 
(Sjortrand, 1937; Miller et al, 1938; Brenner and Merritt, 1942; Chatfield and Dempsey, 1943; 
Turski et al 1989). First description of the pilocarpine model has been done by Tursky and 
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collaborator in 1983 (Tursky et al, 1983a,b) and, from then on, it has been widely used to mimic 
and model human TLE.  
The pilocarpine model is characterized by three different chronological stages: an acute period, of 
status epilepticus instauration, a latent (referred also as silent or quiescent) period, of seizures free 
behaviour, and a chronic period, when spontaneous recurrent seizures occur. 
The acute period is represented, in animals, by rapid changes in behaviour after pilocarpine 
administration. Five minutes after injection, animals begin to be motionless displaying oro-facial 
movements, salivation, eye blinking, twitching of vibrissae and yawning. At 30 minutes, 
discontinuous seizures are observed, which will last until limbic motor seizures take over. The latter 
are accompanied by intense salivation, rearing, upper extremity clonus and falling. Animal is, 
therefore, entered in status epilepticus (Turski et al, 1983a). Usually, 60% of injected animals enter 
status epilepticus (Cavalheiro et al, 1991) which last for a few hours (5 to 6 h) before entering the 
post-ictal coma which lasts 1-2 days. Loss of weight is appreciated in animals undergoing this 
treatment which is recovered after 1 week from pilocarpine injection (Turski et al, 1989) . High 
mortally is associated to this model and increases in relation to the length of status epilepticus 
(Turski et al, 1983a, Turski et al, 1989; Cavalheiro et al, 1991; Liu et al, 1994). Reduction of 
mortality is achieved by stopping status epilepticus with anticonvulsant drugs such as diazepam or 
others.  
EEG-associated-activity perfectly follows ictal and interictal epileptic events in the pilocarpine 
model. Pilocarpine doses capable to develop status epilepticus range between 300 and 400 mg/Kg 
(Turski et al, 1983a, Turski et al, 1989; Cavalheiro et al, 1991; Liu et al, 1994). 
The latent period starts after status epilepticus recovery and is characterized by a seizures free 
period in which a normal behaviour and EEG activity is recorded in the animal. The latent period 
have a variable duration of 1-6 week(s) (Cavalheiro et al, 1991) depending on different factors: 
length of status epilepticus (Lemos and Cavalheiro, 1995; Fujikawa, 1996; Biagini et al, 2006; 
Goffin et al, 2007), pilocarpine dose (Liu et al, 1994), background strain of the animal and age 
(Biagini et al, 2006; Goffin et al, 2007). In this period several pathophysiological rearrangements 
occur in the brain, that might lead to the third phase of the model (spontaneous seizures). Tissue and 
cell alterations in the latent period include: mossy fibber sprouting, interneuron and neuron loss, 
rewiring of synaptic circuits, glial cell activation and ectopic cell proliferation (Dalby and Mody, 
2001; Pitkanen and Sutula, 2002). 
The Chronic period is characterized by spontaneous recurrent seizures (SRSs) with different 
behaviour, all aspects summarized and reclassified by Veliskova (Veliskova, 2006) according to the 
following criteria: 1, staring and mouth clonus; 2, automatisms; 3, monolateral forelimb clonus; 4, 
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bilateral forelimb clonus; 5, bilateral forelimb clonus with rearing and falling; 6, tonic-clonic 
seizure. Usually, SRSs begin as partial seizures (classes 1, 2 or 3) and develop in to secondary 
generalized seizures (classes 4, 5 or 6) (Goffin et al, 2007). Once started, SRSs recur relatively 
regularly for the whole life of the animal and their recurrence has been described as cyclic, 
occurring in definite clusters each 5-8 days or more on average (Goffin et al, 2007; Arida et al, 
1999). SRSs occur more often during the diurnal period (Arida et al, 1999), are associated with 
EEG activity starting from the hippocampus and spreading to the neocortex in 90% of the cases 
(Cavalheiro et al, 1991) and usually last less than 60 seconds (Cavalheiro et al, 1991). 
The main mechanism by which pilocarpine acts in producing this model is its action on the M1 
muscarinic receptor subtype, which causes imbalance between excitatory and inhibitory 
transmission resulting in status epilepticus (Priel and Albuquerque, 2002). This imbalance may be 
due to increased glutamate release (Smolders et al, 1997). This may explain why pilocarpine starts 
its action by stimulation of M1 muscarinic receptors and then, once seizures are activated, is 
sustained by NMDA receptor activation (Nagao et al, 1996; Smolders et al, 1997). A plausible 
molecular explanation may be related to a reduction of voltage and Ca2+ dependent K+ conductance 
(Benardo and Prince 1982) which may favour Ca2+ and Na+ cellular influx, that in turn may be 
responsible for the depolarizing excitatory events exacerbating the seizures (Pumain et al, 1983).  
For the aims of our experiments we focused our attention only on the first stage of the model (acute 
period).   
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AIM OF THIS STUDY 
 
 
The aims for this study lay on the intention to deeply investigate whether Fmr1 mRNA is localized 
in the dendrites of mature neurons, whether the distribution of the mRNA is altered by synaptic 
activation of epileptogenic type, and whether the mRNA is locally translated in response to signals 
that induce synaptic plasticity and epilepsy. This investigation is a part of a wider project in which 
Fmr1 mRNA localization, distribution and translation is studied also in another experimental setting, 
perforant path stimulation. The reported results come from the submitted paper Ferrari et al, based 
on the work performed in collaboration with Claudia Bagni and colleagues, at the University of 
Rome-Tor Vergata, and Oswald Steward and colleagues, at the University of California at Irvine, 
CA. 
 68
MATERIALS AND METHODS 
 
 
Animals 
 
Adult male Sprague-Dawley rats (Harlan) were used for the experiments. Animal care was 
conducted according to the institutional guidelines that are in compliance with national (DL N116, 
GU, suppl 40, 18- 2-1992) and international laws and policies (European Community Council 
Directive 86/609, OJa L 358, 1, December 12, 1987; National Institutes of Health Guide for the 
Care and Use of Laboratory Animals, US National Research Council, 1996). 
 
 
Pilocarpine treatment 
 
To induce seizures, rats (250-300g) received pilocarpine (300 mg/Kg). Within 30 min from 
pilocarpine administration, animals entered a convulsive status epilepticus, which was arrested 2 hrs 
after onset by administration of 10 mg/Kg Diazepam. Animals were killed by anaesthetic overdose 
and perfused (as described below) after 2, 4 or 24 hours from the onset of status epilepticus. Control 
animals received saline and were perfused at matching time points. 
 
 
Preparation of tissue for in situ hybridization and immunostaining 
 
Animals were deeply anesthetized and then perfused with 4% paraformaldehyde in 0.1 M phosphate 
buffered saline (PBS pH 7,4). Brains were removed and postfixed in ice-cold 4% paraformaldehyde 
in 0.1 M PBS. For cryoprotection, brains were placed in 25% sucrose/4% paraformaldehyde/0.1 M 
PBS until the brains sank. Brains were then frozen in cold (-80°C) isopentane or dry ice and stored 
at -80°C until use. Twenty µm sections were cut using a cryostat and either thaw-mounted on 
polylysine-coated slides and stored at –80°C (for in situ hybridization) or left floating in 1X PBS 
and stored at 4°C (for immunocytochemistry experiments). 
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In situ Hybridization 
 
Non-isotopic in situ hybridization was carried out as previously described (Steward et al., 1998). 
Slides that had been stored at –80°C were thawed at room temperature for 5-10 min, and were then 
dried in a 55°C oven for 10-15 min. Sections were post-fixed with 4% paraformaldehyde in 0.1 M 
PBS for 30 min, then rinsed with 0.5X SSC (0.1% DEPC treated) for 5 min. Sections were treated 
with Proteinase K (1.25 µg/ml) for 30 min, rinsed again with 0.5X SSC (0.1% DEPC treated) for 10 
min and air-dried. The sections were covered with 75µl of pre-hybridization buffer (2X SSC, 25% 
formamide, 1% Denhardt’s solution, 10% dextran sulfate, 0.5 mg/ml heparin, 0.5 mg/ml E. coli 
tRNA and 0.25 mg/ml of denatured salmon sperm DNA) and incubated at 42°C for 2-3 hrs. After 
the pre-hybridization, 0.5 µg of digoxygenin-labeled cRNA probe, in 75 µl of hybridization buffer, 
was added to each section. Sections were covered with baked coverslips and incubated overnight at 
55°C in a humidified box with 25% formamide and 2X SSC. The next day, coverslips were 
removed and sections were washed with 2X SSC/1 mM EDTA twice (10 min each). Sections were 
treated with RNAseA for 30 min and then washed twice with 2X SSC/1 mM EDTA. The stringency 
wash was performed at 55°C for 2 hrs in 0.5X SSC/1 mM EDTA. After that, sections were washed 
with 0.5X SSC twice (10 min each at room temperature). Sections were dried and incubated with 
blocking solution (1X TBS, 0.2% Triton-X100, 10% BSA) for 30 min at room temperature. To 
detect the hybridized probes, we used an alkaline phosphatase conjugated anti-digoxygenin Fab 
fragment (1:1000 in blocking solution, 1 hr at 37°C). Sections were rinsed twice with 1X TBS and 
then NBT/BCIP solution was applied overnight (4°C) to detect the alkaline phosphatase. The next 
day, sections were washed with 0.1 M Tris pH 8.5/1 mM EDTA 3 times (10 min each). Then slides 
were briefly rinsed with nanopure water and covered with Kaiser mounting medium (nanopure 
water, gelatin, glycerol). 
 
 
Immunohistochemistry 
 
Free-floating vibratome sections were heat-treated (95°C for 5 min) to recover antigenicity. After 
antigen retrieval, sections were blocked for 2 hrs, at RT, in Mix solution (0.1 M Tris pH 7.4, 0.5% 
Triton-X100, 0.,25% Carrageenan lambda)/10% normal goat serum (NGS) and then incubated 
overnight with anti-FMRP-rAM2 antibodies (1:100) at 4°C. The FMRP (rAM2) antibodies were 
produced by immunizing rabbits against the human C-Terminus of FMRP (Ferrari et al., 2007). 
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Sections were washed with 1X TBS 3 times and then incubated in biotin conjugated secondary 
antibody (goat anti-rabbit IgG, 1: 500) for 2 hrs at room temperature. 
After washing, sections were incubated in Vector ABC kit (Vector, Burlingame, CA) for 1 hr and 
then reacted with DAB and H2O2 for the colorization reaction. Sections were mounted on poly-L-
lysine slides, dehydrated through alcohols to xylene, and coverslipped.  
 
 
Preparation of cRNA probes 
 
For in situ hybridization the following probes were used (Fmr1-3’ UTR, Fmr1 coding) in both sense 
and antisense orientation. The primers used to clone the cDNAs fragments from mouse brain total 
RNA were as follows: 
Fmr1-3’ UTR forward: 5’-GGT AAA GAT CGT AAC CAG AAG-3’ 
Fmr1-3’ UTR reverse: 5’-CAA GTA CAT CAG AGG CAG AAC-3’ 
Fmr1 coding forward: 5’-CCC GGG CGA TGG AGG AGC TGG TGG TGG-3’ 
Fmr1 coding reverse: 5’-GGA ATT CCT GGG GTA CTC CAT TCA CGA GT-3’ 
The cDNA for Fmr1-3’ UTR, was cloned into pGemTeasy vector and linearized with SacII or SacI 
to transcribe, in vitro with SP6 or T7 polymerases, antisense or sense digoxygenin-labeled cRNA 
probes. The cDNA for the Fmr1 coding region was cloned into the EcoR1-Xho1 sites of the 
pBluescript-SK II plasmid and linearized with EcoR1 for antisense cRNA probe synthesis. 
Specificity of the probe for Fmr1 mRNA was assessed performing in situ hybridization and 
Northern blot on Fmr1-KO and WT mice.  
 
 
Optical Density Measurement 
 
Optical density measurements were taken across the granule cell layer/molecular layer, pyramidal 
cell layer/stratum radiatum and pyramidal cell layer/stratum lucidum/stratum radiatum using Image 
J software (version 1.36b). Images were acquired through a Nikon Coolpix digital camera mounted 
on a Zeiss Axioscop microscope (plan-neofluar 20X objective). Densitometric analysis was 
performed on a 350 x 250 µm frame. For each animal and hippocampal subfield, we generated 
curves in which each data point represents the average gray level over a line of 700 pixels 
(corresponding to 350 µm) at a given distance from the cell layer. To compare the different animals, 
each section was positioned to align the cell layer parallel to one border of the field visualized by 
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the camera. For statistical analysis, we used the average grey level measured in 20 µm intervals of 
the different layers in the different hippocampal subfields. The data obtained were analyzed using 
one-way ANOVA and the post hoc LSD test. Values in the graphs illustrate the mean and standard 
error of four to five animals per group. 
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RESULTS 
 
 
Pilocarpine seizures cause dendritic targeting of Fmr1 mRNA and FMRP 
in hippocampus 
 
Because of evidence that loss of FMRP may be associated with epilepsy (Musumeci et al., 2000; 
Chen and Toth, 2001; Berry-Kravis 2002), we assessed whether epileptogenic events (acute 
episodes of status epilepticus) altered the distribution of Fmr1 mRNA or FMRP. To address this 
question, a discrete episode of status epilepticus was induced by treating rats with the muscarinic 
acetylcholine receptor agonist pilocarpine, terminating seizures after 2hrs with diazepam, and 
killing animals 2, 4, and 24 hr later (Turski et al., 1989). The hippocampus is strongly activated 
during pilocarpine-induced status epilepticus, so that dendritic laminae contacted by synapses of 
intrinsic hippocampal pathways are strongly activated (for example, stratum radiatum, which is the 
site of termination of commissural/associational synapses from the CA3 subfield and stratum 
lucidum, which is the site of termination of mossy fibers from dentate granule cells). In situ 
hybridization revealed that level of Fmr1 mRNA was elevated in the stratum radiatum of the CA1 
region (figure 2A-H) and in the stratum lucidum of the CA3 subfield (figure 2I-P). This effect was 
detected 2 and 4, but not 24 hr after the onset of status epilepticus (data not shown for the 24 h 
timepoint). The change of distribution in pilocarpine treated animals compared to control is 
statistically significant as shown in figures 2H and 2P. 
Immunostaining of sections from the same animals revealed that levels of staining in the dendritic 
regions of the CA1 subfield were comparable between controls and treated animals (figure 3A-E). 
In contrast, immunostaining was higher in the stratum lucidum of the CA3 region 2 and 4, but not 
24 hr after the onset of status epilepticus (figure 3F-M). This discrepancy between Fmr1 mRNA and 
FMRP localization in the CA1 region could be due to differences in the timing of accumulation of 
mRNAs vs. protein in different brain areas and/or at particular subsets of synapses. 
Overall, these observations suggest that pilocarpine-induced seizures cause Fmr1 mRNA and 
FMRP to accumulate selectively at particular dendritic domains. 
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Figure 2: Pilocarpine seizures induce dendritic targeting of Fmr1 mRNA in the CA1 and CA3 
(A-C) Part of the coronal brain sections at the level of the dorsal hippocampus labeled with a probe for Fmr1 mRNA in 
control (A), pilocarpine (B) and pilocarpine- diazepam treated conditions (C) at the level of CA1 region, showing 
increased dendritic staining for Fmr1 mRNA after onset of status epilepticus (B and C). Specific areas (insets, D-F) 
marked by yellow, blue and pink lines are enlargements of the areas pointed by the coloured arrows in A, B, C and 
show the differential distribution in dendrites in control and stimulated conditions. (G and H) represent the 
densitometric analysis of the dendritic labeling in the CA1 region, expressed as pixel intensity (0-200 gray level; 
200=white; 0=black) from the cell soma (in micrometers). Data are the means ± standard error of four to five animals 
per group: control (yellow line; n=5), pilocarpine (pilo, pink line; n=5) and pilocarpine-diazepam (pilodiazepam, blue 
line; n=4). (I-K) CA3 region labeled with a probe for Fmr1 mRNA in control (I), pilocarpine (J) and pilocarpine- 
diazepam treated conditions (K)). Specific areas (insets, L-N) marked by yellow, blue and pink lines are enlargements 
of the areas pointed by coloured arrows in I, J, K. (O and P) represent the densitometric analysis of the dendritic 
labeling in CA3 region. Quantification has been performed using “Image J” software as described in Materials and 
Methods. (**p<0,01; *p<0,05. Bars=100 µm) 
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Figure 3: Pilocarpine seizures increases FMRP levels in dendrites of the CA3 region. 
(A-C) Part of the coronal brain sections at the level of the dorsal hippocampus labeled for FMRP in control (A), 
pilocarpine (B) and pilocarpine- diazepam treated conditions (C) at the level of CA1 region, showing no differences in 
FMRP distribution pattern after pharmacological treatments. Graphs (D and E) represent the densitometric analysis of 
the dendritic immunoreactivity in CA1 region, expressed as pixel intensity (0-200 gray level; 200=white; 0=black) from 
the cell soma (in micrometers). Data are the means ± standard error of four to five animals per group: control (yellow 
line; n=5), pilocarpine (pilo, pink line; n=5) and pilocarpine-diazepam (pilo-diazepam, blue line; n=4). (F-H) show 
FMRP level in the CA3 region, with an increased proximal dendritic immunoreactivity after pharmacological treatment. 
Specific areas (insets, I-K) marked by yellow, blue and pink lines are enlargements of the areas pointed by coloured 
arrows in F, G, H. (L and M) represent the densitometric analysis of FMRP dendritic staining in CA3 region. 
Quantification has been performed using “Image J” software as described in Materials and Methods. (*p<0,05. 
Bars=100 µm)  
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DISCUSSION 
 
 
This study, a part of a wider investigation on Fmr1 and FMRP targeting and dendritic expression 
(Ferrari et al, submitted) provides several new insights into the mechanisms underlying the 
expression of FMRP in dendrites. FMRP has been strongly implicated in regulating dendritic 
mRNA translation, especially during the period in which activity-induced synaptic modifications 
are “consolidated”. We show here, for the first time, that Fmr1 mRNA is localized in the dendrites 
of mature neurons in vivo at low levels, supporting and extending previous conclusions based on 
studies of synaptoneurosome fractions from young animals (Weiler et al., 1997; Zalfa et al., 2003) 
and studies of neurons developing in culture (Antar et al., 2004; Ferrari et al., 2007).  Previous 
studies (Hinds et al., 1993; Valentine et al., 2000), performed using radioactive in situ hybridization 
and probes for the coding region of Fmr1 mRNA, did not report detectable levels of Fmr1 mRNA 
in dendrites, although the issue of dendritic localization was not explicitly assessed in these studies. 
The ability to detect labelling in this study may be due to the use of a sensitive non-isotopic in situ 
hybridization procedure, to a slightly different fixation protocol, as well as to a different Fmr1 
mRNA probe. 
In this discussion we will focus our attention on the fact that we report that Fmr1 mRNA and FMRP 
dendritic localization pattern in hippocampus can be modified by epileptogenic stimuli in vivo. Our 
findings suggest a direct involvement of Fmr1 mRNA and FMRP in specific synaptic pathways, 
and indicate that the intra-dendritic distribution of Fragile X mRNA and protein can be modified by 
synaptic activity related to epileptogenesis. The involvement of FMRP in this kind of activity-
dependent modification has been previously suggested based on in vitro experiments (Weiler et al., 
1997; Huber et al., 2002; Li et al., 2002; Antar et al., 2004; Weiler et al., 2004). Our results here 
indicate that Fmr1 mRNA accumulates in activated dendritic laminae in response to epileptic 
stimulation patterns. 
Indeed, the alterations in the dendritic localization of Fmr1 mRNA following a 2hr period of status 
epilepticus supports the conclusion that dendritic localization of Fmr1 mRNA can be regulated by 
synaptic activation. During pilocarpine-induced status epilepticus, principal neurons in the 
hippocampus are strongly activated, thus activating synapses that terminate in stratum radiatum (the 
site of termination of commissural/associational synapses from the CA3 subfield) and stratum 
lucidum (the site of termination of mossy fibers from dentate granule cells). The episode of status 
epilepticus initiates epileptogenic processes that eventually, over a period of days or weeks, make 
the neurons and/or the circuits more prone to seizures. Our results here implicate FMRP in the early 
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stage of the epileptogenic processes. The delivery of FMRP to dendrites could either contribute to 
epileptogenic processes in a positive way, enhancing activity-dependent plasticity, or in a negative 
way by helping to restore synaptic homeostasis after periods of intense, uncontrolled activity. If 
FMRP does modulate the cellular and molecular events that determine seizure susceptibility, this 
could explain the increased prevalence of childhood seizures in people with Fragile X syndrome 
(Berry-Kravis 2002) and increased seizure susceptibility in the mouse model for the syndrome 
(Musumeci et al., 2000; Chen and Toth, 2001). For example, FMRP might stabilize or 
translationally repress mRNA molecules involved in the repression of the epileptic seizure. In 
absence of this/these control(s), susceptibility to seizures would increase. The other possibility is 
that enhanced seizure susceptibility in Fragile X Syndrome has nothing to do with altered 
mechanisms of synaptic plasticity in principal neurons, and instead reflects an alteration in the 
function of GABAergic interneurons. Indeed, there is evidence that GABAergic mechanisms are 
altered in absence of FMRP and BC1 RNA (Centonze et al., 2008; for a recent review see D’Hulst 
and Kooy, 2007). Further studies will be required to elucidate the role of FMRP in epileptogenesis. 
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Chapter IV 
 
Bradykinins and susceptibility to seizures. 
Study on B1 null mouse 
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INTRODUCTION 
 
 
Bradykinins 
 
The biologically active kinins are peptide autacoids. First clues of kinin existence date back to the 
1930s (Kraut et al, 1930; Werle and Grunz, 1939) and, since then, several experimental 
investigations found kinins involved in many biological function. Their main functions are 
explicated in cardiovascular homeostasis, in contraction and relaxation of smooth muscles, in 
inflammation and nociception (Marceau et al, 1998;; Calixto et al, 2000; Couture et al, 2001; Rodi 
et al, 2005). Moreover, Kinins have been recently described as proliferative/anti-proliferative (Patel 
and Schrey, 1992; Dixon and Dennis, 1997; Tsuchida et al, 1999; Alric et al, 2002; Duchene et al, 
2002; Bascands et al, 2003), fibrotic/anti-fibrotic (Wollert et al, 1997; Gallagher et al, 1998; 
Ricupero et al, 2000; Schanstra et al, 2002), angiogenic/anti-angiogenic (Volpert et al, 1996; 
Silvestre et al, 2001; Emanueli et al, 2002) agents, depending on the cellular type taken into 
consideration. The kinin system is also involved in disease states like asthma, allergies, rheumatoid 
arthritis, cancer, endotoxic and pancreatic shock (Marceau et al, 1998; Bhoola et al, 2001). 
Furthermore, kinins are neuromediators of central neuronal pathways associated with the autonomic 
control of blood pressure and nociception (Couture and Lindsey, 2000; Couture et al, 2001) . The 
involvement of kinins in neurological diseases has not been intensively investigated thus far. 
However, recent results suggest their implications in epilepsy, stroke and multiple sclerosis (Leeb-
Lundberg et al, 2005; Rodi et al, 2005). 
The term “kinins” identifies a group of 9-11 amino-acid peptides, including bradykinin (BK), Lys-
bradykinin or kallidin (Lys-BK or KD), T-kinin (Ile-Ser-BK) and their active metabolites (des-
Arg9-kinins). 
Their activation in-vivo follows two different pathways, a plasmatic one and a tissue one, and both 
of them are started by an injury event (fig 1) 
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Fig 1: Biosynthesis of kinins. See text for details. Abbreviations: HMWK, high molecular weight kininogen; LMWK, 
low molecular weight kininogen; BK, bradykinin. 
 
In plasma, after tissue injury inducing the activation of the Hageman factor (factor XII of the 
coagulation cascade), the kallikrein enzyme (kininogenase) is released from plasmatic inactive pre-
kallikrein and catalyzes the conversion of the precursor kininogen HMWK (high molecular weight 
kininogen, 110 kDa) into BK (Fig 1). 
In tissues, kallikrein is activated by proteolytic enzymes produced during trauma and induces the 
release of Lys-BK from the kininogen LMWK (low molecular weight kininogen, 70 kDa), with the 
exception of the rat where BK, rather than Lys-BK, is released (Bhoola et al, 1992) (fig 1). 
HMWK and LMWK derive from alternative splicing of a single gene (Kitamura et al, 1983). Both 
BK and Lys-BK have a very short life-time, less than 30 seconds in serum or when injected in the 
cerebral ventricles (Kariya et al, 1982; Decarie et al, 1996). A kallikreinin-dependent-mechanism 
has also been demonstrated, based on mast cell tryptase and elastase action, that are responsible for 
the production of Met-Lys-BK besides BK and Lys-BK; this alternative pathway of biosynthesis is 
thought to contribute to the prolonged kinin production at inflammatory sites (Kozik et al, 1998). 
Lys-BK and T-kinin can be transformed into BK through the action of aminopeptidases (Couture et 
al, 2000; Kuoppala et al, 2000) (fig. 1). BK and Lys-BK, can be converted in other active 
metabolites des-Arg9-BK and Lys-des-Arg9-BK, by removal of the C-terminal Arg. These 
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biotransformations are catalyzed by a group of enzymes named kininases I: carboxypeptidase N (in 
plasma) and carboxypeptidase M (associated with cell membranes).  
Inactive metabolites are generated by removing the carboxyterminal dipeptides Phe8-Arg9 and Ser6-
Pro7 by kininase II, also termed angiotensin-1 converting enzyme (ACE), an enzyme that is mainly 
located on the luminal membrane of endothelial cells. Another dipeptidyl carboxypeptidase, neutral 
endopeptidase 24.11 (enkephalinase), removes Phe8-Arg9 from BK in vascular walls. Kininase II 
cleaves the C-terminal dipeptide Ser6-Pro7 of BK (1-7) to produce BK (1-5), which is the final 
metabolite of BK and des-Arg9-BK in human plasma (Kuoppala et al, 2000). Studies in humans 
suggest that the BK and the Lys-BK systems are differentially regulated (Duncan et al, 2000). 
 
 
Kinins receptors 
 
Kinins exert their action through two membrane receptors classified as B1 and B2. Both receptors 
have been discovered in the 1970s by Regoli and coworkers (Regoli et al, 1977; Regoli et al, 1978; 
Drouin et al, 1979) and biologically belong to the G-protein-coupled-receptor with seven 
transmembrane domains (Liao et al, 1993; Marceau et al, 1997; Marceau et al, 1998). B1 and B2 
receptors share only part of their primary structure: there is only 36% homology between human B1 
(353 amino acids) and B2 receptors (364 amino acids) (Menke et al, 1994). They also show 
different affinity for BK and its various active derivatives, following this order of agonist potency: 
for B1 receptors, Lys-des-Arg9-BK > Lys-BK ≈ des-Arg9-BK >> BK and for B2, BK ≈ Lys-BK >> 
des-Arg9-BK and Lys-des-Arg9-BK (Leeb-Lundberg et al, 2005).  
 
B1 receptor: B1 receptor is the protein product of a three exon-gene positioned on chromosome 14 
(Leeb-Lundberg et al, 2005). The B1 receptor is mainly activated by des-Arg9 kinin metabolites. In 
particular, Lys-des-Arg9-BK is thought to be the endogenous ligand for this receptor in humans 
(Menke et al, 1994; Regoli et al, 1998; Regoli et al, 2001). This receptor is normally scarcely 
represented and its most prominent biological feature is that it is inducible in consequence of tissue 
injury, infection and under conditions of massive release of cytokines (IL-1b, TNF-a) and growth 
factors, i.e. under pathological situations (Ahluwalia and Perretti, 1996; Marceau et al, 1998; 
Siebeck et al, 1998). In addition, they are induced by the action of the transcription factor NF-kB 
(Bachvarov et al, 1996; Ni et al, 1998; Schanstra et al, 1998)  and by its own agonist (Schanstra et 
al, 1998; Phagoo et al, 1999; Phagoo et al, 2001). This phenomenon occurs directly at the level of 
gene transcription and not through the synthesis of intermediate proteins (Phagoo et al, 2001). The 
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activation of B2 receptors is also thought to induce B1 receptor expression through autocrine 
production of cytokines and the activation of NF-kB (Pan et al, 1996; Phagoo et al, 1999;). 
It is worth noting that B1 receptors with functional haemodynamic functions are induced and 
overexpressed in B2 knockout mice (Duka et al, 2001; Marin-Castano et al, 2002; Duka et al, 2003). 
In contrast with the B2, the B1 receptor internalizes its ligand very slowly and it does not undergo 
desensitization (Austin et al, 1997; Faussner et al, 1998; Marceau et al, 1998; Marceau et al, 2001). 
The main B1 transduction pathway is the activation of phospholipase C (Marceau et al, 1998; 
Couture and Lindsey, 2000) with production of DAG and IP3, which are responsible for the 
activation of PKC and for Ca2+ mobilization, respectively. The B1 receptor can also stimulate the 
release of arachidonic acid through phospholipase A2, which leads to the formation of 
prostaglandins (Bascands et al, 2003) (Fig. 2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Kinin receptors. See text for details. 
Abbreviations: PLC, phospholipase C; DAG: 
diacylglycerol; IP3, inositol triphosphate; PKC, 
protein-kinase C; GC, guanosine cyclase; cGMP, 
cyclic guanosine monophosphate; AC, adenylate 
cyclase; cAMP, cyclic adenosine monophosphate; 
NOS, nitric oxide synthase; NO, nitric oxide; PLA2, 
phospholipase A2; AA, arachidonic acid; PG, 
prostaglandin. 
 
B2 receptor: as reported for B1, B2 receptor is the protein product of a three exon gene on 
chromosome 14 (Leeb-Lundberg et al, 2005). It is preferentially activated by BK and Lys-BK and 
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is thought to mediate acute inflammatory reactions (Dray and Perkins, 1993; Couture et al, 2001) by 
inducing the cascades of both PLC and PLA2. PLA2 releases arachidonic acid (Rang et al, 1991), 
leading to the production of the prostaglandins PGE2 and PGI2, while PLC induces the activation 
of PKC and the mobilization of intracellular calcium (Fig. 2). In consequence of these events, 
neurotransmitters (like excitatory amino-acids and neuropeptides) are released. Furthermore, 
following depolarization, calcium activates adenylate cyclase and guanylate cyclase (leading to the 
production of cAMP and cGMP) and NO synthase (with nitric oxide release by endothelial and 
inflammatory cells). 
After the binding of BK to B2 receptors, BK is internalized together with the receptors, interrupting 
its action (Munoz and Leeb-Lundberg, 1992; Munoz et al, 1993). The B2 receptor can be 
subsequently recycled. 
 
While B2 receptors are responsible for most of the physiological actions of kinins and are mostly 
involved in the acute phase of inflammation, B1 receptors seem to participate essentially in the 
chronic phase (Dray and Perkins, 1993; Dray, 1997; Couture et al, 2001), generating a persistent 
response due to their up-regulation, to their scarce internalization and to the presence of large 
amounts of des-Arg9 kinin metabolites at the inflammatory sites (Decarie et al, 1996) (fig. 3). 
Furthermore, they seem to be especially involved in pathologies with an autoimmune component, 
like rheumatoid arthritis and diabetes. 
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Fig. 3 Coordinated activity of B2 and B1 receptors. Under basal, physiological conditions, while B2 receptors are 
constitutively expressed, B1 receptors are little represented in almost all cell types. Acute pathological events (for 
example acute inflammation, B) cause production of BK and Lys-BK that activate B2 receptors. Prolonged pathological 
events (C) lead to internalization of B2 receptor, biotransformation of BK and Lys-BK into des-Arg9-BK and Lys-des-
Arg9-BK respectively, and up-regulation of B1 receptors. Since B1 receptors do not internalize, this mechanism ensures 
a prolonged cellular response to kinins. See text for further details. Abbreviations: BK, bradykinin, PLC, phospholipase 
C; PLA2, phospholipase A2. 
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The enzymes, the substrates and the receptors of the kallikrein-kinin system have all been identified 
in different areas of the human (Raidoo et al, 1996a; Raidoo et al, 1996b; de Sousa Buck et al, 2002) 
and rat (Kizuki et al, 1994; Chen et al, 2000; Ongali et al, 2003; Cloutier et al, 2004;) central 
nervous system. In particular, tissue kallikrein has been found at high concentrations in the 
hypothalamus, pituitary and pineal gland, but also in the cortex, brainstem and cerebellum, while 
kininases are diffuse in all brain areas (Camargo et al, 1972; Camargo et al, 1973). BK-like 
immunoreactivity has been localized in rat and guinea-pig spinal cord neurons (Lopes and Couture, 
1997; Couture and Lindsey, 2000) and in neuronal cells of the rat hypothalamus, periaqueductal 
gray matter, perirhinal and cingulate cortices, the ventral portion of caudate-putamen, and the lateral 
septal area (Correa et al, 1979). B2 receptors are widely distributed in mammalian brain (Murone et 
al, 1997; Chen et al, 2000; de Sousa Buck et al, 2002; Ongali et al, 2003; Cloutier et al, 2004), 
while in the rat spinal cord they have been identified in the dorsal horn and in particular on the 
terminals of Aδ and C sensory fibbers and of bulbospinal noradrenergic fibbers (Couture et al, 2001; 
Lopes et al, 1995). Thus, it has been suggested that, through B2 receptor activation, kinins exert a 
role of CNS neuromediator, being involved in the control of nociception and blood pressure 
(Couture and Lindsey, 2000). B1 receptors are very scarcely represented in the normal rat brain, 
based on autoradiographic evidence (Ongali et al, 2003). In contrast, their mRNA distribution has 
been detailed throughout the rostral-caudal extent of the monkey brain and spinal cord, 
demonstrating a basal level of expression in the nonhuman primate CNS (Shughrue et al, 2003). 
However, evidence is still lacking for establishing whether this B1 receptor mRNA is translated into 
functional receptors. 
 
 
Bradykinins and epilepsy 
 
To date, bradykinins have been scarcely investigated in their implication in pathologies of the CNS. 
B2 receptors have been implicated in the early phase of stroke-induced inflammation, and the 
selective blockade of these receptors may prove therapeutically useful. In contrast, B1 antagonists 
have been found to be detrimental for neuronal recovery and survival, indicating that B1 receptor 
activation is implicated in the late phase of stroke-induced inflammatory phenomena, in tissue 
repair. Thus, selective B1 receptor agonists may be of therapeutic value in this phase (Rodi et al, 
2005). 
B1 receptors may represent a control-point for inflammation in the CNS, usually associated to 
Multiple Sclerosis, and B1 receptor analogues may be useful in the therapy of this disease. The 
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critical point for the treatment of this pathology is the dual effect of B1 receptor activation: the use 
of an antagonist would be appropriate to block the increased permeability of the blood-brain-barrier, 
while an agonist would be more beneficial for preventing the infiltration of T-lymphocytes in the 
CNS. Both types of molecules need to be tested in an animal model of multiple sclerosis to address 
this fundamental issue (Rodi et al, 2005). 
In epilepsy, our main field of interest, bradikinins and derivatives have proven to be involved in the 
pathology, in a series of works. Kinin receptors have been reported to be modified after epileptic 
stimuli. Ongali and coworkers demonstrated, using autoradiography, that, in fully kindled rats, B2 
receptors decrease in many brain areas and B1 receptors increase mainly in the kindling recruited 
limbic areas (Ongali et al, 2003). At the protein level, in agreement with Ongali, other studies have 
shown that, in pilocarpine model (Arganaraz et al, 2004b) and in human sclerotic hippocampi from 
patient suffering of TLE, B1 receptors are increased (Perosa et al, 2007). However, discrepancies 
were found on the protein expression for B2 receptors (Arganaraz et al, 2004b; Perosa et al, 2007): 
in the pilocarpine model and in human hippocampi of TLE patients an increase in B2 receptors was 
observed. At gene expression level, data in the literature are sometimes in agreement with the 
protein findings (Pereira et al, 2008; Silva et al, 2008) and sometimes they are not a (Silva et al, 
2008). Unaltered levels of B1 receptor mRNA in human ippocampi in TLE patients have been 
shown by Perosa and collaborators (Perosa et al, 2007) and unaltered mRNA levels for B2 receptors 
have been demonstrated by Silva and colleagues in the pilocarpine model applied to B1 KO mice. 
Functionally, bradikinin B1 receptors have been involved in epileptic response as favouring 
glutamate release in fully kindled rats both in slices (Bregola et al, 1999) and using microdialysis 
(Mazzuferi et al, 2005).  
Susceptibility to seizures of B1 and B2 null mouse models have been explored using pilocarpine. 
B1 KO mice proved to be less prone to seizures, implicating that the B1 receptor contributes to 
epileptic hyper-excitability, while B2 KO mice were more susceptible to seizures, leading to the 
speculation that B2 receptors may play a protective role (Arganaraz et al, 2004a; Silva et al, 2008).  
Taken together, this data suggest a deep implication of the bradykinin system in epilepsy. It is still 
unclear, howevere, whether this is detrimental for epileptogenesis or protects brain tissue from 
damage. B1 receptors seem mainly associated with tissue excitability (Bregola et al, 1999; 
Mazzuferi et al, 2005; Arganaraz et al, 2004a,b; Silva et al, 2008). In the pilocarpine model, 
however, B2 receptors mRNA have been shown to be increased in the chronic phase when 
spontaneous seizures occur (Arganaraz et al, 2004b; Silva et al, 2008). It has been suggested that 
this phenomenon exerts a protective effect, because B2 KO mice experience a greater number of 
spontaneous recurrent seizures in the chronic period after pilocarpine (Arganaraz et al, 2004a).  
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Thus, it is still difficult to draw a complete frame for the involvement of bradykinins in epilepsy and, 
therefore, more work is needed to complete the picture.          
 
 
B1 KO mice 
 
At the turn of the century, Pesquero and colleagues created the B1 deficient mouse model by using 
gene targeting technology (Pesquero et al, 2000). Absence of the target receptor was shown at the 
mRNA level in several tissues that normally express the B1 receptor. B1 KO mice are grossly 
normal and fertile and, due to the gene disruption, are insensitive to contractile response of smooth 
muscle after application of des-Arg9-BK. In basal condition they show to be normotensive but, 
when stimulated with bacterial lipopolysaccharide (LPS), they display a markedly hypotensive 
response that goes back to normal around 40 minutes after the stimulation. The response to 
intrathoracic injection of carrageenan or of the specific B1 agonist, des-Arg9-BK, which produces 
pleurisy with plasma extravasation and leukocyte infiltration in normal rodents, is abolished in B1 
KO mice. Under the same conditions polymorph nucleate cell invasion is absent in B1 deficient 
mice, but endothelial permeabilization and mononuclear cell infiltration are preserved.   
B1 KO mice response to pain in the tail-flick assay was not different from wild-type mice. However, 
by using the hot plate assay, B1 receptor-deficient mice showed significant hypoalgesia when 
mildly painful heat stimuli were used (52.5 and 55.5°C); with more intense stimuli (58.5°C), 
however, no difference was observed between the genotypes. In addition, capsaicin evoked reduced 
nocifensive behaviors in B1-deficient compared with wild-type mice. Finally, in a model of acute 
inflammatory pain, the formalin test, B1-deficient mice showed significantly less nocifensive 
behaviors in the early and late phase. 
Noxious heat has been shown to directly induce inward currents in isolated nociceptors that can be 
potentiated by kinins (Cesare and McNaughton, 1996; Cesare et al, 1999). To prove that, patch-
clamp experiments have been carried out demonstrating that B1 deficient mice are normal in this 
respect. 
The hypoalgesia described in the hot plate, capsaicin, and formalin tests have been studied further 
by testing the spinal processing of the nociceptive input: B1 KO mice showed a reduced response to 
the late component of spinal cord afferent transmission due to activation of C-fibbers activated by 
des-Arg9-BK in vivo. The early component of spinal cord afferent transmission, brought about by 
A-fibbers, is unaltered in B1 KO mice. Indeed, this component is bradykinin-receptor independent. 
Moreover, repetitive electrical stimulation (500 mA, 500 ms) of the L5 dorsal root at 1 Hz for 20 s 
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induces an increase in the size of the ventral root potential. This type of plasticity has been termed 
wind-up. In B1-deficient mice, wind-up was reduced by about 50% compared with wild-type 
animals, confirming that this receptor modifies nociceptor-induced plasticity of synaptic 
transmission at the spinal level.  
This mouse model has been created to deeply investigate the alterations of the normal homeostasis 
brought about by disruption of the B1 receptor gene. The data reported above are only a few of the 
many already published that better define the model and the implication of B1 in several 
physiological pathways. To date, exploration of the susceptibility to seizures has been reported in 
the pilocarpine model by Arganaraz and colleagues and Silva and coworkers, who demonstrated a 
reduced epileptic phenotype in the B1 KO mice. Since Bradykinin has been reported to play a role 
in epileptic phenomena, this mouse model seems to be a good tool to investigate the functional role 
of B1 receptor in epileptic experimental condition. For these reasons, we applied the kindling and 
the kainate model to B1 KO mice.      
 
 
Kindling 
(For an extensive review of the model see “Models of seizures and epilepsy” Pitkanen A., Schwartzkroin P.A. and Moshé S.L. (2006) Elsevier 
Academic Press) 
 
 
Discovered by Goddard in 1967, the so called “kindling” refers to the phenomenon by which the 
repeated administration of an initially sub-convulsive electrical stimulation within a specific brain 
region results in the progressive intensification of the evoked seizure activity. Indeed, kindling 
initially present itself as a simple phenomenon, whereby provocation of electrically stimulated focal 
seizures induces a clear progressive change in response over daily repetitions. The progression 
begins on the first day with a brief, low frequency electrographic afterdischarge (AD) at the 
electrode tip, which is associated with little behaviour response. However, the complexity of the 
phenomenon begins to appear as the response evolves over days, resulting eventually in the 
triggering of long, high frequency ADs associated with strong convulsive responses (Goddard et al, 
1969). In the end, the induced increase in susceptibility to additional seizures is permanent and the 
brain that underwent kindling may be defined as an “epileptic” brain. This progression is readily 
apparent from all limbic and most forebrain stimulation sites, but it is dramatic from temporal lobe 
structures, such as the amygdala and the adjacent cortices, including the piriform, perirhinal, insular 
and entorhinal cortices (McIntyre et al, 1999). For these reasons, the kindling phenomenon has been 
employed extensively as a chronic model of temporal lobe epilepsy. It is the daily progressive 
increase in response severity in both EEG and behaviour that defines kindling.  
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Practically, kindling consists of the implantation of a bipolar electrode in the chosen brain area 
using stereotaxic surgery. Beginning one week after surgery, animals will undergo evaluation of 
AD threshold and, subsequently, daily stimulation with a single train of bipolar rectangular pulses, 
at the minimal amplitude capable of evoking a focal discharge in the surgically implanted area. This 
patter of stimulation does not initially provoke any behavioural response but, in time, a 
progressively worsening seizure activity will be observed, which can be easily quantified (Racine et 
al, 1972). 
By the description reported above, it is clear that kindling is initially a model of focal partial 
seizures, that, with daily repetitive stimulation, recruits more brain areas, starting from the 
implanted focus and spreading to connected circuits, becoming a model of complex partial seizures 
with secondary generalization. In particular, in kindling there is loss of consciousness, a feature of 
complex seizures. Even though seldom reported, continuous triggering of seizures over time may 
lead to spontaneous seizures in the chronic period of the model (Pinel and Van Oot, 1975; Wada 
and Osawa 1976; Michalakis et al, 1998) making this experimental approach a possible model for 
studying epileptogenesis.   
 
  
Kainate  
(For an extensive review of the model see “Models of seizures and epilepsy” Pitkanen A., Schwartzkroin P.A. and Moshé S.L. (2006) Elsevier 
Academic Press) 
 
This model has been developed from the initial observations of Nadler and of Ben-Ari and 
Lagowska (Ben-Ari and Lagowska, 1978; Nadler et al, 1978) that kainate induces repetitive 
seizures and neuronal damage in the hippocampus, reminiscent of temporal lobe epilepsy. From 
then on, kainate administration has been used to produce rodent preparations that display the 
general characteristics of human acquired or injury-induced epilepsy, including TLE.  
The kainate model has at least three major stages: 1) the initial hours-long episode of status 
epilepticus, 2) the days to weeks-long seizure-free latent period and 3) the gradual development and 
progressive increase in the frequency of recurrent spontaneous seizures. The final stage is generally 
permanent and defines chronic epilepsy. During all the three stages anatomical, cellular and 
molecular changes occur and seem to develop in parallel with the acute and chronic 
neuropathological alterations reported in humans. These changes and plastic modifications suggest, 
like in the pilocarpine model, that status epilepticus triggers epileptogenic mechanisms.  
Kainate administration may be done in different ways and this may change the outcome of the 
model. Single dose administration usually allows a rapid onset of status epilepticus, but lethality 
may be very high or some animals may never enter in status epilepticus. The first problem may be 
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solved by stopping status epilepticus using a benzodiazepine like diazepam. The second problem 
may be overcome by giving a second dose of kainate. The kainate model obtained by single high 
dose seems to reduce the probability in generating animals with robust spontaneous recurrent 
seizures. Repeated lower (subconvulsant) doses, titrated until the development of status epilepticus, 
is another protocol found in the preparation of the kainate model. This approach increases the 
success in inducing status epilepticus and dramatically reduces lethality (Hellier et al, 1998). 
Spontaneous seizures seem to occure more frequently using this experimental approach.  
The kainate model associates to plastic alterations such as neuronal cell loss, reactive gliosis, 
network rearrangement, metabolic changes and genetic and molecular modifications. These features 
are in line with those found in human mesial temporal lobe epilepsy, making kainate model a good 
tool to explore mechanisms underlying epileptogenesis and epileptic induced modifications.  
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AIM OF THE STUDY 
 
 
The aim of this study has been to add new insights on the involvement of bradykinin in epilepsy by 
exploring the susceptibility of B1 null mice to two different epilepsy models: kindling, an electric 
model, and kainate, a chemical model.  
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MATERIALS AND METHODS 
 
 
B1 null mice 
 
Adult male B1 null mice and their controls C57Bl/6 were used for all experiments. The animals 
were housed under standard conditions: constant temperature (22–248C) and humidity (55–65%), 
12 h dark–light cycle, free access to food and water. Procedures involving animals and their care 
were carried out in accordance with European Community and national laws and policies. All 
efforts were made to minimize animal suffering, and to reduce the number of animals. 
 
 
Kindling 
 
For kindling, a twisted bipolar electrode was implanted in the right amygdala (coordinates 
according to Paxinos and Franklin (Paxino and Franklin, 2001) and experimentally adjusted: 3,2 
mm lateral and 1,2 mm posterior to bregma, 4,7 mm deep from dura) under isoflurane anaesthesia. 
Animals were allowed seven days to recover, and then stimulated to uncover their threshold. 
Threshold has been found for each animal following a protocol with a starting stimulation of 40 
microA and increasing it by 20 microA every 2 minutes until a single after discharge of at least 5 
seconds became evident on EEG recording. Animals not producing an AD below 300 microA were 
not included in the study. Starting from the day after evaluation of threshold, animals were 
stimulated once daily with a single 1 s train of bipolar pulses (1 ms, 60 Hz, mA 25% above after-
discharge threshold). For every animal, behaviour (staging according to Janumpalli et al, 1998) and 
the duration of afterdischarge measured in the right amygdala were recorded after each stimulation. 
Kindling criteria were reached after three consecutive stage 4 or higher seizures.  
 
 
Kainate 
 
Animals were treated with kainic acid (20 mg/kg, i.p.). After administration of this chemo-
convulsant, seizure activity was monitored for 2 h by blind investigators, and scored as follows: 1, 
chewing and drooling; 2, head nodding; 3, unilateral forelimb clonus; 4, bilateral forelimb clonus; 5, 
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bilateral forelimb and/or hindlimb clonus with falling; 6, running or jumping seizure; 7, tonic 
hindlimb extension; 8, death (Janumpalli et al, 1998). Control mice were aged-matched litter-mates 
which were injected with saline. 
The cumulative seizure score (CS) was rated as the sum of the maximal scores recorded in the 24 5 
min intervals of the 2 h observation. The seizures index (SI) was rated as follows; 0, no severe 
seizures in the two hour observation; 1, one seizure classified equal or above to 4 in the two hour 
observation interval; 2, 2-5 seizures classified equal or above 4 in the two hour observation interval; 
3, 6-10 seizures classified above or equal to 4 in the two hour observation interval; 4, more than 10 
seizures classified above or equal to 4 in the two hour observation interval; 5, death of the animal 
within the two hour of observation. Latency was calculated as the time between the injection and 
the first class 4 or higher.  
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RESULTS 
 
 
Kindling development 
 
The kindling procedure has been applied to B1 KO mice in order to compare the response of WT 
and B1 KO mice. Indeed, B1 KO mice displayed a lower threshold compared to WT mice, 
indicating an already hyper-excitable tissue (195,38 ± 17,71 microA for WT; 143,08 ± 14,47 
microA for KO; p=0,0313) (Fig 4A) . This reflected in the number of stimulations required to reach 
the kindled condition that resulted lower in KO compared to WT mice (8,6 ± 0,6 stimulations in 
WT; 5,7 ± 0,8 stimulations in KO; p=0,0048) (Fig 4B). The average class experienced by mice for 
each stimulation resulted higher in B1 deficient mice in comparison with their C57Bl control mice. 
This phenomenon is more evident during the initial phases of kindling development (Fig 4D). The 
duration of the electrical manifestation (the after-discharge, AD) was slightly longer in B1 null mice 
than in controls (Fig 4C).  
Taken together, the results of this experiment lead to the conclusion that B1 KO mice are more 
prone to kindling than normal mice.     
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Figure. 4: kindling development in B1 KO mice. (A) Comparison of average threshold values between KO and WT mice: a lower threshold has been 
found in KO mice compared to WT. (B) number of stimulations required to reach the kindling status. A reduced number of stimulation is required in 
KO mice compared to controls. (C) Average AD duration for each stimulus in WT and KO mice. (D) Average seizure class (staged as in Janumpalli 
et al, 1998) during kindling development. KO mice show higher class for each stimulation than WT control mice.   
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Susceptibility to kainate seizures 
 
To explore the susceptibility to seizures of B1 null mice, WT and B1 KO age matched mice were 
injected with 20 mg/kg i.p. kainate, and their behavior monitored for 2 h thereafter. This dose of 
kainate was chosen because it causes relatively mild seizures in WT animals, allowing proper 
observation of possible alterations in the B1 KO group. The response to kainate was consistent with 
a latent epileptic phenotype in B1 KO mice. (1) Behavioral seizure scores, based on two distinct 
scoring systems, were significantly increased in B1 KO mice (Fig. 5 B and C). (2) The latency to 
generalized seizure onset (in the subset of animals displaying generalized seizures) was 
significantly shorter in B1 KO mice (26±4 min versus 76±12 min in WT; p < 0.001, Student’s t test 
for nonpaired data) (Fig. 5A). (3) The percentage of animals displaying generalized seizures (stage 
4 or higher) was much higher in the B1 KO group: 6 of 13 WT animals (46,15%) versus 13 of 14 
kainate-treated B1 KO mice (92,86%). During most of the 2 h after kainate administration, the 
seizure class was indeed higher for the B1 KO mice compared with the WT group (Fig. 5E). 
Furthermore, at the end of the observation period, all WT animals were behavioral seizure-free, 
whereas some B1 KO mice were still seizing (2 of 14, i.e., 14,28%). (4) Lethality was increased: 
whereas no WT mouse of 13 treated with kainate died, 4 of 14 (28,57%) B1 KO died during 
observation (i.e., in the first 2 h after kainate administration) (Fig. 5D). 
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Fig. 5: Kainate seizure susceptibility in B1-deficient mice. (A) Latency to the first generalized (grade 4 or above) 
seizure after 20 mg/kg i.p. kainate injection in WT (green) and B1-deficient (KO) (black) mice. (B) Cumulative seizure 
score, rated as the sum of the scores recorded in each 5-min interval of the 2 h following kainate injection. (C) Seizure 
index: 0, no seizure; 1, 1 severe (class 4–5) seizure; 2, 2–5 severe seizures; 3, 6–10 severe seizures; 4, >10 severe 
seizures, or very severe seizures (class 6–7); 5, death within 2 h. (D) lethality expressed in %. (E) Time course of 
seizure grade. Data are the mean±SE of 13 WT and 14 KO mice per group; *P<0.05, **P<0.01; Mann–Whitney U test 
for panels B and C; ***P<0.001 Student's t test for panel A. 
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DISCUSSION 
 
 
In this work we report that B1 KO mice are hyper excitable in two epilepsy models. In kindling, 
animals displayed a lower AD threshold and this observation was confirmed in all the other 
parameters we analysed: a higher number of stimulations was required to reach the kindled state, 
the average class and the average AD duration was higher for each stimulation. In the kainate model, 
B1 KO mice resulted more prone to seizures than their age-matched controls, displaying higher 
severity scores.  
These results are in contrast with what we were expecting based on our previous results (Bregola et 
al, 1999: Mazzuferi et al, 2005) and reports from other groups (Arganaraz et al, 2004a; Arganaraz et 
al, 2004b; Perosa et al, 2007; Pereira et al, 2008; Silva et al, 2008). Indeed, our previous findings 
demonstrated B1 receptors to mediate a higher excitatory response in the late phase of  kindling, by 
increasing glutamate release (Bregola et al, 1999: Mazzuferi et al, 2005). Following this observation, 
the rest of the literature reports excitatory implications for B1 receptor in the pilocarpine model 
(Arganaraz et al, 2004a; Arganaraz et al, 2004b; Pereira et al, 2008; Silva et al, 2008).  
What is then the role of the bradykinin system in epilepsy? Our findings may suggest a protecting 
role for B1 receptors. However, another hypothesis may be proposed: that B2 receptor may be over-
expressed in the brain of B1 KO mice as a compensatory response to the absence of the inducible 
B1 receptors. Based on this hypothesis, the increased acute response to kainate may be explained by 
a high compensatory expression of B2 receptors. B2 receptors have already been demonstrated to 
be involved in the acute inflammatory response (Couture et al, 2001; Rodi et al, 2005;) and 
inflammation has been shown to have a compounding effect on brain tissue excitability (Vezzani et 
al, 2002; Vezzani and Granata, 2005). The same hypothesis may apply to kindling and its evolution. 
The lower threshold of B1 KO, when compared to controls, may be due to the putative excitatory 
effect of B2 receptor over-expression. Accordingly, if one assumes higher density of B2 receptors 
in many brain areas, this would imply a lower resistance to seizure spread and the faster kindling 
development that we observed. These speculations obviously need an experimental investigation 
which will involve a more accurate analysis of the B1 KO brain, in particular an evaluation of B2 
receptor density. 
In conclusion, it can be stated that, in both epileptic models we used, B1 KO mice displayed the 
same increased susceptibility to seizures, allowing the speculation that B1 receptors may be 
somehow protective in epilepsy or that a compensatory over-expression of B2 receptors may be 
detrimental for epilepsy phenomena. Both hypotheses are amenable of experimental investigation. 
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CONCLUDING REMARKS 
 
 
The genetics of epilepsy are undoubtedly complicated. Genetic mechanisms are fundamental to 
explain why seizures appear, progress, worsen or eventually disappear. The data reported in this 
thesis add contributions to the vast amount of work that has been done to uncover how genes and 
their expression may be involved or influence the outcome of epilepsy.  
In the Unverricht-Lundborg disease, a primary genetic epilepsy, we proposed a putative cellular and 
physiological mechanism that may underlie the pathophysiology of the onset and development of 
the disorder. In Fragile X, a major genetic defect that presents as a mental retardation syndrome 
with epilepsy, we demonstrated that Fmr1 (the gene whose silencing causes the disease) is activated 
during epileptic phenomena and may contribute to the plastic response occurring after an ictal event. 
Finally, we found that brain excitability is exacerbated in B1 null mice after electric and chemical 
epileptic insults, suggesting that modifications in the bradykinin system create a fertile condition in 
which other genetic or acquired factors may induce epilepsy.   
Increasing our knowledge of the genetic mechanisms and the consequent molecular, cellular, 
histological and physiological alterations is of key importance for a better treatment of epilepsy: this 
goal is highly expected by millions of people who deal with seizures and their consequences every 
day. In a wider perspective, the knowledge retrieved by genetic studies on epilepsy may help to 
shed light on the physiological functions of the brain.  
 
